https://iridex.com RSS feeds for Iridex 60 https://iridex.com:443/Default.aspx?tabid=59&articleType=ArticleView&articleId=63#Comments 0 https://iridex.com/DesktopModules/DnnForge%20-%20NewsArticles/RssComments.aspx?TabID=59&ModuleID=524&ArticleID=63 https://iridex.com:443/DesktopModules/DnnForge%20-%20NewsArticles/Tracking/Trackback.aspx?ArticleID=63&PortalID=0&TabID=59 https://iridex.com:443/Default.aspx?tabid=59&articleType=ArticleView&articleId=63 Mountain View, CA -  May 31, 2024 -  Iridex Corporation (NASDAQ: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, will showcase its latest non-incisional glaucoma treatments at the 16th European Glaucoma Society (EGS) Congress in Dublin, Ireland, from June 1-4, 2024. Attendees are invited to explore Iridex's glaucoma laser solutions at Booth #55. "We are pleased to take part in the EGS, where we will highlight our versatile laser platforms and advanced technologies, providing a continuum of care from early to end-stage glaucoma," said Steven J Koufos; Vice President, Global Marketing. MicroPulse Transscleral Laser Therapy (TLT) A versatile, non-incisional, and repeatable procedure for glaucoma treatment using the Iridex Cyclo G6® Laser System and MicroPulse P3® Delivery Device. Iridex-hosted MicroPulse TLT Drylab Session Sunday, June 2, 2024, titled “Non-incisional Glaucoma Treatment – The Versatility of MicroPulse Transscleral Laser Therapy” in Liffey Room 2, 10:30am-12:00pm Attendees of the Iridex-hosted MicroPulse TLT Drylab session will be able to explore the versatility of MicroPulse Transscleral Laser Therapy. For those unable to attend in person, we are also offering live streaming of the session via IPTV, providing global access to cutting-edge glaucoma treatments and innovations. Posters on Iridex-patented MicroPulse® Technology Comparison of one-year outcomes between combined micropulse transscleral diode cyclo-photocoagulation with phacoemulsification and combined Hydrus microstent with phacoemulsification Safety and efficacy of micropulse transscleral cyclophotocoagulation in eyes affected by advanced primary glaucoma Micropulse transscleral cyclophotocoagulation in the treatment of secondary ocular hypertension in the eyes with vitreous hemorrhage Continuous-wave Transscleral Cyclophotocoagulation (CW-TSCPC) Continuous-wave Transscleral Cyclophotocoagulation (CW-TSCPC) Performed with the Cyclo G6® using G-Probe® and G-Probe Illuminate® delivery devices, offering a cost- effective, safe, and effective non-incisional glaucoma care solution. Dedicated symposium on Continuous-wave and MicroPulse laser Associacion Argentina de Glaucoma Symposium - Continuous Diode and Micropulse Laser: The practice, its scope and current result MicroPulse® Laser Trabeculoplasty (MLT) Supported by Iridex 532 nm, 577 nm, and 810 nm laser platforms, MLT is a reasonable first-line therapy to address concerns of patient compliance with medical therapy, reduce patient costs and avoid medication side effects. Stela Vujosevic, MD, PhD, FEBO; Head of Medical Retina Unit at the University Eye Clinic, MultiMedica in Milan, Italy, commented, “Since 2009, I have been researching, and clinically applying, Iridex’ MicroPulse technology for safe and efficacious treatment of retinal disorders. More recently, my colleagues and I investigated the changes in intraocular pressure, functional parameters, and multimodal imaging in patients with ocular hypertension after MicroPulse Laser Trabeculoplasty. We are excited to share our research at EGS.” For more information, please contact your Iridex sales professional or Iridex customer service at 1.650.940.4700 or customerservice@Iridex.com. About Iridex In 2024, Iridex Corporation celebrates its 35th anniversary as a worldwide leader in developing innovative and versatile laser-based medical systems, delivery devices, and consumable instrumentation for the ophthalmology market. The Company’s proprietary MicroPulse® technology delivers a differentiated treatment that provides safe, effective, and proven therapy for targeted sight- threatening eye conditions. Iridex’ products treat glaucoma, diabetic macular edema, and other retinal diseases. Iridex products are sold in the United States and Germany through a direct sales force and in more than 100 countries through a network of independent distributors. For more information, visit www.Iridex.com. Iridex Media Contact Joan Stauffer Director, Marketing & Clinical Communications jstauffer@Iridex.com isigma Tue, 11 Jun 2024 11:24:00 GMT f1397696-738c-4295-afcd-943feb885714:63 https://iridex.com:443/Default.aspx?tabid=59&articleType=ArticleView&articleId=62#Comments 0 https://iridex.com/DesktopModules/DnnForge%20-%20NewsArticles/RssComments.aspx?TabID=59&ModuleID=524&ArticleID=62 https://iridex.com:443/DesktopModules/DnnForge%20-%20NewsArticles/Tracking/Trackback.aspx?ArticleID=62&PortalID=0&TabID=59 https://iridex.com:443/Default.aspx?tabid=59&articleType=ArticleView&articleId=62 MOUNTAIN VIEW, Calif., February 6, 2024 – Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today announced the grant of the European Patent EP 3009093, entitled "Laser System with Short Pulse Characteristics and its Methods of Use”. This groundbreaking patent further protects Iridex’s intellectual property encompassing laser systems in ophthalmology and related fields, for technology that enhances safe and effective laser treatments. Iridex is the exclusive provider of MicroPulse® devices that utilize the patented technology.Revolutionizing Eye Care with Precision and Safety The patented technology delivers a state-of-the-art laser system capability for delivering short, controlled-width pulse trains. This technology is designed to minimize the risk of full-thickness retinal damage and vision loss, a common concern with traditional laser treatments with numerous clinical studies demonstrating its safety and efficacy in retina and glaucoma applications and beyond. By employing a diode pump source and a frequency-doubled solid-state visible laser, the system produces a pulsed output with controlled thermal effects, focusing on tissue-specific photoactivation without photocoagulation damage.Overcoming Limitations of Current Technologies This innovative MicroPulse technology addresses the limitations of current continuous wave visible lasers. It incorporates advanced software and hardware components in its feedback range control system, effectively managing energy fluctuations and enhancing safety during treatments. The system's ability to produce controlled-width pulse trains with reduced power fluctuations represents a novel leap forward in medical laser technology. This technology covers the full laser wavelength range from 520nm-615 nm. In European countries the Unitary Patent will be enforced by members of the Unified Patent Court as well as the United Kingdom.A Commitment to Advancing Medical Laser Treatments "This advancement enhances both the safety and effectiveness of laser treatments in ophthalmology and the patent grant affirms our exclusive position as the only authorized provider of MicroPulse technology," stated David Bruce, President and CEO of Iridex Corporation.About Iridex CorporationIn 2024, Iridex Corporation celebrates its 35th anniversary as a worldwide leader in developing, manufacturing, and marketing innovative and versatile laser-based medical systems, delivery devices and consumable instrumentation for the ophthalmology market. The Company’s proprietary MicroPulse® technology delivers a differentiated treatment that provides safe, effective, and proven treatment for targeted sight-threatening eye conditions. Iridex’s current product line is used for the treatment of glaucoma and diabetic macular edema (DME) and other retinal diseases. Iridex products are sold in the United States through a direct sales force and internationally primarily through a network of independent distributors into more than 100 countries. For further information, visit the Iridex website at www.iridex.com.Iridex, and MicroPulse® are registered trademarks of Iridex Corporation, Inc. © 2023 Iridex Corporation. All rights reserved.Safe Harbor StatementThis announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Act of 1934, as amended, including those statements concerning clinical expectations and commercial trends, market adoption and expansion, demand for and utilization of the Company's products and results and expected sales volumes. These statements are not guarantees of future performance and actual results may differ materially from those described in these forward-looking statements as a result of a number of factors. Please see a detailed description of these and other risks contained in our Quarterly Report on Form 10- Q filed with the Securities and Exchange Commission on November 20, 2023. Forward-looking statements contained in this announcement are made as of this date and will not be updated.Media ContactSteven Koufosskoufos@iridex.com host Tue, 06 Feb 2024 14:38:00 GMT f1397696-738c-4295-afcd-943feb885714:62 https://iridex.com:443/Default.aspx?tabid=59&articleType=ArticleView&articleId=61#Comments 0 https://iridex.com/DesktopModules/DnnForge%20-%20NewsArticles/RssComments.aspx?TabID=59&ModuleID=524&ArticleID=61 https://iridex.com:443/DesktopModules/DnnForge%20-%20NewsArticles/Tracking/Trackback.aspx?ArticleID=61&PortalID=0&TabID=59 https://iridex.com:443/Default.aspx?tabid=59&articleType=ArticleView&articleId=61 Mountain View, CA –January 25, 2024 - Iridex Corporation, headquartered in Mountain View, California, and Imperial College Healthcare NHS Trust in London, today announced the first patient enrollment in a collaborative medical research study and registry evaluating the treatment of glaucoma with MicroPulse® Transscleral Laser Therapy (TLT) using Iridex’ Cyclo G6® Laser and the MicroPulse P3® Delivery Device. This partnership establishes a large-scale enrollment platiorm to advance clinical research.David I. Bruce, President and CEO of Iridex, shared: "The first patient enrollment in this partnership with Imperial College Healthcare NHS Trust is the first step toward multicenter participation enabling a large- scale view and significant in-country impact of our MicroPulse® technology.”The study, titled "MicroPulse Transscleral Laser Therapy: A Prospective UK Study," is set to expand Iridex’s global clinical portiolio, through its commitment to funding essential components of the 3-year study and providing a custom-designed and secure database management system.Professor Philip Bloom, Consultant Ophthalmic Surgeon at Imperial College Healthcare NHS Trust, emphasized the importance of rapid expansion: “We are delighted at Imperial to be able now to offer this minimally invasive treatment for glaucoma. Expansion to include other units will be crucial in advancing glaucoma treatment in the UK. Our partnership with Iridex is key to enhancing this study's reach and impact.”The Western Eye Glaucoma Department of the Imperial College Healthcare NHS Trust is the first to implement MicroPulse® TLT as part of this clinical research registry, adhering to NICE IPG692 guidelines. The registry and study is structured for expanded participation from other UK providers to join the program and build enrollment for large patient cohorts.Both Iridex and Imperial College Healthcare NHS Trust are dedicated to conducting this study in accordance with the strictest ethical and regulatory standards and look forward to welcoming additional sites to join the program. The collaboration symbolizes the company’s shared vision for advancing medical science with MicroPulse® TLT. It promises significant insights and advancements in glaucoma laser therapy, potentially revolutionizing treatment approaches and enhancing patient care.Iridex would like to thank and acknowledge Carleton Optical Equipment Ltd, located in Chesham, England, for providing clinical trial training, service, and support.About Iridex CorporationIn 2024, Iridex Corporation celebrates its 35th anniversary as a worldwide leader in developing, manufacturing, and marketing innovative and versatile laser-based medical systems, delivery devices and consumable instrumentation for the ophthalmology market. The Company’s proprietary MicroPulse® technology delivers a differentiated treatment that provides safe, effective, and proven treatment for targeted sight-threatening eye conditions. Iridex’s current product line is used for the treatment of glaucoma and diabetic macular edema (DME) and other retinal diseases. Iridex products are sold in the United States through a direct sales force and internationally primarily through a network of independent distributors into more than 100 countries. For further information, visit the Iridex website at www.iridex.com.Iridex, and MicroPulse® are registered trademarks of Iridex Corporation, Inc. © 2023 Iridex Corporation. All rights reserved.Safe Harbor StatementThis announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Act of 1934, as amended, including those statements concerning clinical expectations and commercial trends, market adoption and expansion, demand for and utilization of the Company's products and results and expected sales volumes. These statements are not guarantees of future performance and actual results may differ materially from those described in these forward-looking statements as a result of a number of factors. Please see a detailed description of these and other risks contained in our Quarterly Report on Form 10- Q filed with the Securities and Exchange Commission on November 20, 2023. Forward-looking statements contained in this announcement are made as of this date and will not be updated.Media ContactSteven Koufosskoufos@iridex.com host Thu, 25 Jan 2024 14:58:00 GMT f1397696-738c-4295-afcd-943feb885714:61 https://iridex.com:443/Default.aspx?tabid=59&articleType=ArticleView&articleId=60#Comments 0 https://iridex.com/DesktopModules/DnnForge%20-%20NewsArticles/RssComments.aspx?TabID=59&ModuleID=524&ArticleID=60 https://iridex.com:443/DesktopModules/DnnForge%20-%20NewsArticles/Tracking/Trackback.aspx?ArticleID=60&PortalID=0&TabID=59 https://iridex.com:443/Default.aspx?tabid=59&articleType=ArticleView&articleId=60 MOUNTAIN VIEW, CA – January 11, 2023 – Iridex Corporation, a global leader in innovative laser-based medical systems for the treatment of eye diseases, proudly announces the US launch of its next- generation platform Iridex 532® and Iridex 577® Lasers alongside its 35th anniversary celebration. The announcement was made ahead of their official showcase at the Hawaiian Eye and Retina 2024 Meeting from January 13-19, 2024.Both lasers harness multiple treatment modes including continuous-wave and Iridex’ patented MicroPulse® Technology and an intuitive touchscreen interface providing a wide range of clinical control options and features to optimize the treatment of retinal disorders and glaucoma.David Bruce, President and CEO of Iridex Corporation, said, “The launch of the new Iridex 532 and Iridex 577 Lasers stands as a testament to our 35 year heritage of providing advanced laser solutions to ophthalmologists worldwide. These innovations mark a pivotal moment for us, blending modern technology with user-centric design to ensure optimized treatments for retinal disorders and glaucoma.”After previewing the new Iridex 577 nm Laser, Dr. Sam Mansour, Medical Director of the Virginia Retina Center, commented, “I was very pleased with the compact design and intuitive user interface. Its treatment-session recordings enhance therapeutic tracking from subsequent laser sessions, and the rapid maneuverability between console menus will undoubtedly improve patient flow. Having used Iridex laser systems for 30 years, I can attest to the highly dependable quality of their products."Product Highlights:Comprehensive Treatment Reports: Physicians can create detailed reports of treatment parameters for every procedure. These reports can be easily managed and downloaded to a USB drive.Configurable Preset Filters: Customizable filters, allowing for simple program management and selection via the new preset management tool enabling customizable selections by procedure and by individual doctor.Enhanced User Experience: The multi-functional single control knob ensures simplified console navigation. Additionally, the 7” high-resolution touchscreen display offers an interactive experience, allowing physicians to navigate seamlessly between options.MicroPulse® Laser Applications: MicroPulse®, a laser delivery modality that adds fine control of photothermal effects in laser photocoagulation, is a tissue-sparing solution for the treatment of retinal diseases and glaucoma.About Iridex CorporationIn 2024, Iridex Corporation celebrates its 35th anniversary as a worldwide leader in developing, manufacturing, and marketing innovative and versatile laser-based medical systems, delivery devices and consumable instrumentation for the ophthalmology market. The Company’s proprietary MicroPulse® technology delivers a differentiated treatment that provides safe, effective, and proven treatment for targeted sight-threatening eye conditions. Iridex’s current product line is used for the treatment of glaucoma and diabetic macular edema (DME) and other retinal diseases. Iridex products are sold in the United States through a direct sales force and internationally primarily through a network of independent distributors into more than 100 countries. For further information, visit the Iridex website at www.iridex.com.Iridex, and MicroPulse® are registered trademarks of Iridex Corporation, Inc. © 2023 Iridex Corporation. All rights reserved.Safe Harbor StatementThis announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Act of 1934, as amended, including those statements concerning clinical expectations and commercial trends, market adoption and expansion, demand for and utilization of the Company's products and results and expected sales volumes. These statements are not guarantees of future performance and actual results may differ materially from those described in these forward-looking statements as a result of a number of factors. Please see a detailed description of these and other risks contained in our Quarterly Report on Form 10- Q filed with the Securities and Exchange Commission on November 20, 2023. Forward-looking statements contained in this announcement are made as of this date and will not be updated.Media ContactSteven Koufosskoufos@iridex.com host Fri, 12 Jan 2024 14:38:00 GMT f1397696-738c-4295-afcd-943feb885714:60 https://iridex.com:443/Default.aspx?tabid=59&articleType=ArticleView&articleId=59#Comments 0 https://iridex.com/DesktopModules/DnnForge%20-%20NewsArticles/RssComments.aspx?TabID=59&ModuleID=524&ArticleID=59 https://iridex.com:443/DesktopModules/DnnForge%20-%20NewsArticles/Tracking/Trackback.aspx?ArticleID=59&PortalID=0&TabID=59 https://iridex.com:443/Default.aspx?tabid=59&articleType=ArticleView&articleId=59 Action Retains Full Patient Access to MicroPulse® Transscleral Laser TreatmentMOUNTAIN VIEW, Calif., December 28, 2023 – Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today announced all five Medicare Administrative Contractors (“MACs”) retired their local coverage determinations (“LCDs”) that were scheduled to take effect on January 29, 2024. Iridex and other stakeholders opposing the LCDs have engaged with the MACs throughout the comment period to advocate for continued patient access to clinically proven safe and effective glaucoma treatments. The Company applauds the decision which effectively retains reimbursement and full access for Medicare patients to all Iridex cyclophotocoagulation products. “We appreciate the engagement with us by the MAC administrators, from the initial correction of criteria for coverage to the conference call with the group to discuss appropriate broadening of qualifying patients. By retiring the LCDs, the MACs have supported continued access to advanced patient care like MPTLT,” said David I. Bruce, President & CEO, Iridex Corporation.“We thank the numerous glaucoma surgeons across the country, as well as the various societies, notably the American Academy of Ophthalmology, the American Glaucoma Society, the American Society of Cataract and Refractive Surgery, and the Outpatient Ophthalmic Surgery Society for their support and advocacy throughout the process. The groundswell of reaction to the LCDs was critical in providing persuasive feedback during the Notice Period before effectiveness, leading to this action in support of glaucoma patient care." Between October 24th, 2023 and November 9th, 2023, five of the seven MACs published LCDs targeting MIGS procedures, which also partially restricted criteria for coverage of cyclophotocoagulation reimbursement. Due to these proposed LCDs, the cyclophotocoagulation procedures performed by Iridex’s G6 laser system and probes would have been partially affected by restrictions of the criteria to deem the procedure medically necessary and provide coverage. As of today, all five MACs, WPS Government Health Administrators, Palmetto GBA, Celerian Group Company, National Government Services, and Noridian Healthcare Solutions, have now issued statements that the final LCDs will not go into effect on January 29, 2024. As a result, there will be no change in January 2024 to the current Medicare coverage for MIGS procedures performed with Iridex MicroPulse® TLT. About Iridex Corporation Iridex Corporation is a worldwide leader in developing, manufacturing, and marketing innovative and versatile laser-based medical systems, delivery devices and consumable instrumentation for the ophthalmology market. The Company’s proprietary MicroPulse® technology delivers a differentiated treatment that provides safe, effective, and proven treatment for targeted sight-threatening eye conditions. Iridex’s current product line is used for the treatment of glaucoma and diabetic macular edema (DME) and other retinal diseases. Iridex products are sold in the United States through a direct sales force and internationally primarily through a network of independent distributors into more than 100 countries. For further information, visit the Iridex website at www.iridex.com. Iridex, and MicroPulse® are registered trademarks of Iridex Corporation, Inc. © 2023 Iridex Corporation. All rights reserved.Safe Harbor Statement This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Act of 1934, as amended, including those statements concerning clinical expectations and commercial trends, market adoption and expansion, demand for and utilization of the Company's products and results and expected sales volumes. These statements are not guarantees of future performance and actual results may differ materially from those described in these forward-looking statements as a result of a number of factors. Please see a detailed description of these and other risks contained in our Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 20, 2023. Forward-looking statements contained in this announcement are made as of this date and will not be updated. Contact Information Media Contact Steven Koufosskoufos@iridex.com Investor Relations Contact Philip TaylorGilmartin Groupinvestors@iridex.com host Fri, 29 Dec 2023 17:45:00 GMT f1397696-738c-4295-afcd-943feb885714:59 https://iridex.com:443/Default.aspx?tabid=59&articleType=ArticleView&articleId=58#Comments 0 https://iridex.com/DesktopModules/DnnForge%20-%20NewsArticles/RssComments.aspx?TabID=59&ModuleID=524&ArticleID=58 https://iridex.com:443/DesktopModules/DnnForge%20-%20NewsArticles/Tracking/Trackback.aspx?ArticleID=58&PortalID=0&TabID=59 https://iridex.com:443/Default.aspx?tabid=59&articleType=ArticleView&articleId=58 The new Iridex PASCAL combines industry-leading speed and precision pattern scanning, Endpoint Management Technology, Pattern Scanning Laser Trabeculoplasty, and now, MicroPulse Technology, in an integrated laser platform using half the footprint of its predecessor.MOUNTAIN VIEW, Calif., April 19, 2023 -- Iridex Corporation (Nasdaq: IRIX), a provider of innovative laser-based medical products for the treatment of glaucoma and retinal diseases, today announced the full market launch of the next generation Iridex PASCAL. The new PASCAL platform, first offered in limited release beginning late 2022, provides an advanced technology package combining fast and precise pattern scanning capabilities, Endpoint Management Technology, Pattern Scanning Laser Trabeculoplasty, and MicroPulse® Technology in a smaller, ergonomically-optimized integrated laser platform.“Our full U.S. launch of the next generation PASCAL platform brings a new standard to the scanning laser market, with its premium performance, throughput-focused user interface and expanded treatment capabilities delivered in about half the space,“ said David I. Bruce, President and CEO of Iridex. “By integrating the traditional electronics box into the treatment table and adding our clinically proven MicroPulse Technology, we now offer physicians a broader choice of premium treatment modalities in a compact, ergonomic system to address a wide array of patient needs.”The Iridex PASCAL offers three tissue-sparing technology options: MicroPulse Mode is Iridex’s proprietary and patented technology. It chops a continuous-wave laser beam into sequences of short, repetitive, low-energy pulses separated by longer rest periods which allows the tissue to cool between laser pulses. An extensive bibliography of clinical research demonstrates its safety and efficacy for the treatment of retinal diseases and glaucoma. Endpoint Management (EpM) is a pattern subthreshold retinal laser therapy that uses a unique algorithm to control laser power and pulse duration, optimizing the therapeutic effect.Pattern Scanning Laser Trabeculoplasty provides a rapid and precise computer-guided treatment that applies a sequence of patterns onto the trabecular meshwork to reduce intraocular pressure. “Having all three of these advanced treatment modalities in one platform widens my clinical reach while freeing up valuable practice space,” said Dr. Victor H Gonzalez of Gulf Coast Eye Institute in McAllen, Texas. “High performance, compact solutions like these broaden the resources at our disposal, allowing us to deliver outstanding, individualized care to more patients with glaucoma and retinal disease.”The new Iridex Pattern Scanning Laser (PASCAL) offers a smaller physical footprint, intuitive touchscreen controls, and ADA-compliant wheelchair accessibility. The PASCAL product line continues to efficiently deliver large laser patterns reducing treatment time and patient discomfort during treatment. The innovative four-fiber beam design improves depth of focus during treatment, ensuring consistent energy delivery across multiple tissue elevations and in the far periphery of the retina. Intuitive user interface provides easy access to a wide variety of pattern variations, and the auto advance feature delivers sequential patterns without taking physician’s eyes away from oculars. The Iridex PASCAL is currently available in 577 nm (yellow) or 532 nm (green) models. About IridexIridex is a worldwide leader in developing innovative and versatile laser-based medical systems, delivery devices, and consumable instrumentation for the ophthalmology market. The Company’s proprietary MicroPulse® technology delivers a differentiated treatment that provides safe, effective, and proven therapy for targeted sight-threatening eye conditions. Iridex’s products treat glaucoma, diabetic macular edema, and other retinal diseases. Iridex products are sold in the United States and Germany through a direct sales force and in more than 100 countries through a network of independent distributors. For more information, visit www.iridex.com.Iridex Media ContactJamie HallPRECISIONeffect724.417.0167jamie.hall@precisionvh.com host Mon, 19 Jun 2023 19:50:00 GMT f1397696-738c-4295-afcd-943feb885714:58 https://iridex.com:443/Default.aspx?tabid=59&articleType=ArticleView&articleId=57#Comments 0 https://iridex.com/DesktopModules/DnnForge%20-%20NewsArticles/RssComments.aspx?TabID=59&ModuleID=524&ArticleID=57 https://iridex.com:443/DesktopModules/DnnForge%20-%20NewsArticles/Tracking/Trackback.aspx?ArticleID=57&PortalID=0&TabID=59 https://iridex.com:443/Default.aspx?tabid=59&articleType=ArticleView&articleId=57 Mountain View, CA — September 26, 2022 — Iridex Corporation (NASDAQ: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, announces the appointment of Sean Teo and Michael Wu to the Iridex team as International Sales Area Managers for Asia Pacific. Sean and Michael bring over 40 years of combined expertise in sales, marketing and management of lasers and medical devices for ophthalmology in the Asia Pacific region to Iridex. Michael served as sales and distribution manager for Asia at Ellex Medical, a maker of ophthalmic laser and ultrasound systems where he successfully launched many new products in the Asian market. Sean spent many years as Clinical Product Manager for the Asia Pacific region at Topcon Medical Laser Systems/ OptiMedica, where he managed product life cycle, developed product training programs, and provided distributor support for marketing and sales plans. “It’s a pleasure welcoming both Sean and Michael to our International team. Their sales and experience in developing sales account strategies, managing clinical experience programs and selling laser products will be a great addition to Iridex.” said Bassem Bouhabib, Vice President, International Sales, Iridex. “I am excited to be a part of this outstanding team,” said Sean. “Iridex has a strong foundation not only of innovative products, but also of clinical and service support programs. I look forward to building strong customer relationships as we grow our business.”“I am honored to join the Iridex team,” said Michael. “Iridex is a world leader in the development and marketing of versatile laser-based medical systems, and I look forward to being part of such an extraordinary team as we continue growing glaucoma and retina laser markets in Asia Pacific region.” “It’s great to have Sean and Michael join the Iridex team. They bring a wealth of experience in sales and marketing to the Iridex customers in the Asia Pacific marketplace,” said Dave Bruce, CEO of Iridex Corporation.About IridexIridex is a worldwide leader in developing innovative and versatile laser-based medical systems, delivery devices, and consumable instrumentation for the ophthalmology market. The Company’s proprietary MicroPulse® technology delivers a differentiated treatment that provides safe, effective, and proven therapy for targeted sight-threatening eye conditions. Iridex’s products treat glaucoma, diabetic macular edema, and other retinal diseases. Iridex products are sold in the United States and Germany through a direct sales force and in more than 100 countries through a network of independent distributors. For more information, visit www.iridex.com.Iridex Media ContactJamie HallPRECISIONeffect724.417.0167jamie.hall@precisionvh.com host Mon, 26 Sep 2022 20:05:00 GMT f1397696-738c-4295-afcd-943feb885714:57 https://iridex.com:443/Default.aspx?tabid=59&articleType=ArticleView&articleId=56#Comments 0 https://iridex.com/DesktopModules/DnnForge%20-%20NewsArticles/RssComments.aspx?TabID=59&ModuleID=524&ArticleID=56 https://iridex.com:443/DesktopModules/DnnForge%20-%20NewsArticles/Tracking/Trackback.aspx?ArticleID=56&PortalID=0&TabID=59 https://iridex.com:443/Default.aspx?tabid=59&articleType=ArticleView&articleId=56 Mountain View, CA — April 5, 2022 — Iridex Corporation (NASDAQ: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, announces the appointment of Juan Carlos Torres to the Iridex team as the International Sales Area Manager for Latin America and Canada (LACA).Juan Carlos Torres brings over 22 years of expertise in developing and managing sales of ophthalmic products in the LACA region. “His experience in selling consumable surgical laser products, as well as capital diagnostic and treatment equipment, will help Iridex reconfirm its distinction as a trusted supplier for innovative and versatile laser systems, delivery devices, and consumables to physicians and distributors in Latin America and Canada,” said Bassem Bouhabib, Vice President, International Sales, Iridex.Specialized in opening and managing international markets, Juan Carlos is a strong leader in directing and motivating sales team members and distributor networks to exceed targets. “I am proud to join Iridex. It is truly a pleasure and privilege to have this unique opportunity to join such an outstanding team and continue developing and growing the glaucoma and retina laser markets with my colleagues in the industry,” said Juan Carlos.“I am very pleased to welcome Juan Carlos to our sales team,” said Dave Bruce, CEO of Iridex. “Juan Carlos’s extensive management and sales experience in the ophthalmic industry and LACA market makes him the perfect candidate for our international team.”About IridexIridex is a worldwide leader in developing innovative and versatile laser-based medical systems, delivery devices, and consumable instrumentation for the ophthalmology market. The Company’s proprietary MicroPulse® technology delivers a differentiated treatment that provides safe, effective, and proven therapy for targeted sight-threatening eye conditions. Iridex’s products treat glaucoma, diabetic macular edema, and other retinal diseases. Iridex products are sold in the United States and Germany through a direct sales force and in more than 100 countries through a network of independent distributors. For more information, visit www.iridex.com.Iridex Media ContactJamie HallPRECISIONeffect724.417.0167jamie.hall@precisionvh.com host Tue, 05 Apr 2022 14:45:00 GMT f1397696-738c-4295-afcd-943feb885714:56 https://iridex.com:443/Default.aspx?tabid=59&articleType=ArticleView&articleId=55#Comments 0 https://iridex.com/DesktopModules/DnnForge%20-%20NewsArticles/RssComments.aspx?TabID=59&ModuleID=524&ArticleID=55 https://iridex.com:443/DesktopModules/DnnForge%20-%20NewsArticles/Tracking/Trackback.aspx?ArticleID=55&PortalID=0&TabID=59 https://iridex.com:443/Default.aspx?tabid=59&articleType=ArticleView&articleId=55 MOUNTAIN VIEW, Calif., January 11, 2022 -- Iridex Corporation (Nasdaq: IRIX) today provided preliminary unaudited operational and financial results for the fourth quarter and full-year ended January 1, 2022. Fourth Quarter 2021Total revenue expected to be $15.1 million to $15.3 million, approximately 24% revenue growth over $12.3 million reported for the fourth quarter of 2020Cash and cash equivalents of approximately $23.8 million as of January 1, 2022, representing a net cash burn of $1.8 million in the fourth quarter, and $5.3 million for the full year 2021Sold 15,200 Cyclo G6® probes in the fourth quarter of 2021, 13% above the prior year quarterSold 90 Cyclo G6® Glaucoma Laser Systems in the fourth quarter of 2021, compared to 57 in the prior year quarterFull Year 2021Total revenue expected to be $53.7 million to $53.9 million, compared to 2020 revenue of $36.3 millionSold 58,200 Cyclo G6® probes, compared to 45,800 in the prior yearSold 243 Cyclo G6® Glaucoma Laser Systems compared to 174 in the prior year“Throughout 2021 our team continued to deliver strong results, despite the underlying challenges posed by the ongoing pandemic, leading to revenue growth of nearly 50% year over year,” said David I. Bruce, President and CEO of Iridex. “Our commitment to investing in sales and marketing, securing broader distribution partnerships and key product line enhancements were all important components of our success in 2021, and positions us well for further advancements in 2022. We strongly believe there is a tremendous opportunity to expand our core markets as we continue to drive adoption of our MicroPulse technology for patients suffering from moderate-to-severe glaucoma and retinal disease.” These preliminary results are based on management's initial analysis of operations for the quarter and year ended January 1, 2022 and are subject to completion of the Company’s year-end financial reporting processes, further internal review, potential adjustments and audit by the Company's external auditors. About IridexIridex Corporation is a worldwide leader in developing, manufacturing, and marketing innovative and versatile laser-based medical systems, delivery devices and consumable instrumentation for the ophthalmology market. The Company’s proprietary MicroPulse® technology delivers a differentiated treatment that provides safe, effective, and proven treatment for targeted sight-threatening eye conditions. Iridex’s current product line is used for the treatment of glaucoma and diabetic macular edema (DME) and other retinal diseases. Iridex products are sold in the United States through a direct sales force and internationally primarily through a network of independent distributors into more than 100 countries. For further information, visit the Iridex website at www.iridex.com. Safe Harbor StatementThis announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Act of 1934, as amended, including those statements concerning the future momentum, demand and utilization of the Company's products, financial guidance and results and expected sales volumes. These statements are not guarantees of future performance and actual results may differ materially from those described in these forward-looking statements as a result of a number of factors. Please see a detailed description of these and other risks contained in our Quarterly Report on Form 10-Q for the third quarter, filed with the Securities and Exchange Commission on November 12, 2021. Forward-looking statements contained in this announcement are made as of this date and will not be updated.Investor Relations ContactLeigh Salvo(415) 937-5404investors@iridex.com host Thu, 13 Jan 2022 20:45:00 GMT f1397696-738c-4295-afcd-943feb885714:55 https://iridex.com:443/Default.aspx?tabid=59&articleType=ArticleView&articleId=54#Comments 0 https://iridex.com/DesktopModules/DnnForge%20-%20NewsArticles/RssComments.aspx?TabID=59&ModuleID=524&ArticleID=54 https://iridex.com:443/DesktopModules/DnnForge%20-%20NewsArticles/Tracking/Trackback.aspx?ArticleID=54&PortalID=0&TabID=59 https://iridex.com:443/Default.aspx?tabid=59&articleType=ArticleView&articleId=54 An international expert consensus panel will discuss best practices in dosing and patient selection using MicroPulse TLT on November 6, 2021 Panel members scheduled for discussions at the Iridex booth during AAO meeting on November 13-15th Mountain View, CA — November 5, 2021 — Iridex Corporation (NASDAQ: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, announces that an international consensus panel of ten glaucoma experts will discuss MicroPulse Transscleral Laser Therapy and their conclusions for proper dosing and patient selection on November 6 at 10:00am PT/ 1:00pm ET. In the live discussion, attendees will learn recommendations for treatment optimization and settings with the MicroPulse P3® Probe, understand the concept of fluence and the importance of sweep speed, as well as identify the clinical drivers for patient selection, outcomes, and safety. “As Micropulse TLT emerges as a key tool in the management of glaucoma, this panel convened to execute a complete analysis of the clinical, technical, practical evidence and experience to date with the MicroPulse P3 and created a consensus document with recommendations for the worldwide clinical application of MicroPulse TLT,” said Tomas Grippo, MD. “Our findings will help providers understand the concept of fluence and the importance of sweep speed, as well as identify the most important clinical drivers for patient selection, outcomes, and safety.” To learn more about the discussion and consensus panel, visit www.Iridex.com/consensus. Iridex at AAO Iridex will present its products and services at the upcoming American Academy of Ophthalmology November 13-15th in New Orleans, LA and will feature opportunities for attendees to meet with glaucoma and retinal physicians from around the world who are experts in the use and application of Iridex lasers. Opportunities include: Lasers and Latte Join Iridex on Saturday, November 13 from 10:00AM – 4:00PM and Sunday, November 14 from 11:00AM – 4:00PM at booth #844 This is an excellent opportunity to ask experts questions and better understand the safety, efficacy, durability, and versatility of the various procedures performed with lasers to treat glaucoma and retinal diseases. Nineteen laser experts, including Robert J. Noecker, MD; Brian A. Francis, MD; Sam E. Mansour, MD; and Nathan Radcliffe, MD, will be available to discuss experiences, surgical pearls and best practices. To find out specific times and available experts, visit https://www.Iridex.com/aao. Skills Transfer Lab Sunday, November 14, from 10:30 AM - 12:30 PM in the glaucoma lab (room 353 - 355). Two Iridex glaucoma procedures, MicroPulse Transscleral Laser Therapy and Continuous Wave Transscleral Cyclophotocoagulation, will be featured in one of AAO's Skills Transfer Labs. The title of the course is "Lasers in Glaucoma," and its director will be Lisa S. Gamell, MD. This course is part of the AAO program; participation requires an AAO registration. The course number is LAB128A. About Iridex Iridex is a worldwide leader in developing innovative and versatile laser-based medical systems, delivery devices, and consumable instrumentation for the ophthalmology market. The Company’s proprietary MicroPulse® technology delivers a differentiated treatment that provides safe, effective, and proven therapy for targeted sight-threatening eye conditions. Iridex’s products are used to treat glaucoma, diabetic macular edema, and other retinal diseases. Iridex products are sold in the United States and Germany through a direct sales force and in more than 100 countries through a network of independent distributors. For more information, visit www.Iridex.com. Iridex Media Contact Jamie Hall Pascale Communications, LLC. (724) 417-0167 jamie@pascalecommunications.com host Fri, 05 Nov 2021 19:36:00 GMT f1397696-738c-4295-afcd-943feb885714:54 https://iridex.com:443/Default.aspx?tabid=59&articleType=ArticleView&articleId=53#Comments 0 https://iridex.com/DesktopModules/DnnForge%20-%20NewsArticles/RssComments.aspx?TabID=59&ModuleID=524&ArticleID=53 https://iridex.com:443/DesktopModules/DnnForge%20-%20NewsArticles/Tracking/Trackback.aspx?ArticleID=53&PortalID=0&TabID=59 https://iridex.com:443/Default.aspx?tabid=59&articleType=ArticleView&articleId=53 MOUNTAIN VIEW, Calif., May 11, 2021 -- Iridex Corporation (Nasdaq: IRIX) today reported financial results for the first quarter ended April 3, 2021. First Quarter Highlights Closed strategic collaboration with Topcon Corporation netting $19.5 million in new funds Record first quarter revenue of $12.0 million, an increase of 33% from the $9.0 million in the prior year period 10% from new products acquired from Topcon Cyclo G6® product family revenue of $3.3 million, an increase of 15% year-over-year 13,600 Cyclo G6 probes sold, a 4% year-over-year increase despite continued COVID-19 impacts International sales of Cyclo G6 probes increased by 18%, setting a new quarterly record 64 Cyclo G6 Glaucoma Laser Systems sold, compared to 38 in the prior year period Retina product revenue grew 61% year-over-year to $6.7 million 16% from sales of PASCAL® products acquired from Topcon Cash at quarter-end of $28 million First new 810 Laser sold in March Showcased 810 Laser and PASCAL Synthesis™ at the 2021 Hawaiian Eye Meeting in May “We enjoyed a strong start to 2021 and our positive momentum continued with revenue that exceeded pre-COVID levels, setting a record for first quarter revenue. During the quarter, we saw international adoption of our Cyclo G6 probes rebound strongly, leading to a new first quarter high in Cyclo G6 probe sales. Additionally, we saw strong performance in our retina business, which was further bolstered by the initial sales of PASCAL products acquired from Topcon,” said David I. Bruce, President and CEO of Iridex. “The investments we made in our product portfolio over the past year and a half are really starting to pay off for the company, particularly with respect to our enhanced retina products. Our focus is now shifting to expand our sales and marketing programs, where we are broadening efforts to demonstrate the many benefits of our non-incisional glaucoma therapy. We intend to leverage our strengthened balance sheet following the Topcon transaction, and pursue the expanding global opportunities we see in both our glaucoma and retina product portfolios,” concluded Bruce. First Quarter 2021 Financial Results Revenue for the three months ending April 3, 2021 increased 33% to $12.0 million from $9.0 million during the same period of the prior year. Excluding newly acquired PASCAL products, revenue increased 19% over the first quarter of 2020. Gross profit for the first quarter of 2021 increased to $4.9 million, a 41% gross margin, compared to $3.9 million, a 43% gross margin, in the same period last year. The gross margin reduction was primarily attributable to a higher portion of revenue coming from wholesale capital equipment sales. Operating expenses for the first quarter of 2021 increased 22% to $6.8 million compared to $5.6 million in the same period of the prior year, mainly due to additional expenses in PASCAL operations and non-recurring Topcon transaction and integration expenses. Net Loss for the first quarter of 2021 was $2.0 million, compared to $1.7 million in the same period of the prior year. Net Loss on a per share basis was $0.14 versus $0.12 last year. Cash usage in the first quarter was $1.1 million, including approximately $0.5 million of non-recurring Topcon transaction payments, which resulted in cash of $28 million at quarter-end. Guidance for Full Year 2021 Iridex expects total revenue for fiscal year 2021 to be $48 million to $51 million, reflecting growth of 32% - 40% over fiscal year 2020. In addition, Cyclo G6 probe sales of 56,000 to 59,000 and Glaucoma Laser System sales of 250 to 275 are expected in 2021. Webcast and Conference Call Information Iridex’s management team will host a conference call today beginning at 2:00 p.m. PT / 5:00 p.m. ET. Investors interested in listening to the conference call may do so by dialing (844) 707-0665 for domestic callers or (703) 326-3030 for international callers, using conference ID: 1282162. A live and archived webcast of the event will be available on the “Investors” section of the Company’s website: www.Iridex.com. About Iridex Iridex is a worldwide leader in developing innovative and versatile laser-based medical systems, delivery devices and consumable instrumentation for the ophthalmology market. The Company’s proprietary MicroPulse® technology delivers a differentiated treatment that provides safe, effective, and proven treatment for targeted sight-threatening eye conditions. Iridex’s current product line is used for the treatment of glaucoma, diabetic macular edema and other retinal diseases. Iridex products are sold in the United States and Germany through a direct sales force and in more than 100 countries through a network of independent distributors. For more information, visit www.Iridex.com. Safe Harbor Statement This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Act of 1934, as amended, including those statements concerning the transactions described above. Such statements include those referring to the transaction described above and the benefits related thereto. These statements are not guarantees of future performance and actual results may differ materially from those described in these forward-looking statements as a result of a number of factors. Please see a detailed description of these and other risks contained in our Annual Report on Form 10-K for the fiscal year ended December 28, 2019, and Quarterly Reports on Form 10-Q for subsequent fiscal quarters, each of which was filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date and will not be updated. Investor Relations Contact Leigh Salvo (415) 937-5404 investors@Iridex.com host Tue, 11 May 2021 23:00:00 GMT f1397696-738c-4295-afcd-943feb885714:53 https://iridex.com:443/Default.aspx?tabid=59&articleType=ArticleView&articleId=52#Comments 0 https://iridex.com/DesktopModules/DnnForge%20-%20NewsArticles/RssComments.aspx?TabID=59&ModuleID=524&ArticleID=52 https://iridex.com:443/DesktopModules/DnnForge%20-%20NewsArticles/Tracking/Trackback.aspx?ArticleID=52&PortalID=0&TabID=59 https://iridex.com:443/Default.aspx?tabid=59&articleType=ArticleView&articleId=52 MOUNTAIN VIEW, Calif., March 22, 2021 -- Iridex Corporation (Nasdaq: IRIX) today reported financial results for the fourth quarter and year ended January 2, 2021. Fourth Quarter Highlights Total revenue in the fourth quarter increased 5% to $12.3 million year-over-year Sold 13,500 Cyclo G6® probes, same as the prior year, despite continued impacts from COVID-19 US Sales of Cyclo G6 probes increased by 8%, setting a quarterly record Sold 57 Cyclo G6 Glaucoma Laser Systems, compared to 107 the prior year, attributed to the Company’s strategic shift toward probe utilization and continued COVID-related capital purchase deferrals Retina related product revenue grew nearly 11% year-over-year Recently released product enhancements drove capture of previously deferred customer orders Fourth quarter gross margin increased by over 400 bps to 45.4% compared to the prior year Increased average selling prices combined with further efficiencies in manufacturing and overhead Cash burn in the fourth quarter was $0.3 million, resulting in ending cash of $11.6 million 9% reduction in operating expenses versus prior year MicroPulse® Transscleral Laser Therapy (TLT) was included in the European Glaucoma Society (EGS) Terminology and Guidelines for Glaucoma and presented at its Annual Meeting in December Subsequent to quarter end, the Company entered into a strategic collaboration with Topcon Corporation resulting in $19.5 million cash to Iridex Topcon purchased distribution rights in certain Asia Pacific and EMEA markets Iridex purchased the PASCAL® product line Topcon purchased approximately 10% of Iridex equity “Despite the challenges relating to COVID-19, our strategic initiatives generated increased demand for Iridex products that has enabled us to exceed our pre-COVID-19 revenue from the fourth quarter of the prior year,” said David I. Bruce, President and CEO of Iridex. “We saw upside in the fourth quarter from demand due to recently launched product improvements and some rebound of capital equipment purchases in the retina business. In glaucoma, US probe sales grew 8%, despite continued COVID-19 impact. We’re pleased to see the positive response to our new products and that momentum carrying into the first quarter of 2021.” Mr. Bruce continued, “Our efforts on product improvements has steadily strengthened our competitive position, from the well-received improvements to our MicroPulse® P3 probe, to the fourth-quarter introduction of our LIO Plus Laser Indirect Ophthalmoscope (LIO) and continuing into 2021 with the launch of a new 810 wavelength laser, the first in a family of new lasers offering substantial savings in manufacturing costs and gross margin improvement.” “We are confident that our new alliance with Topcon Corporation will further improve Iridex’s strategic positioning. Thanks to increased capital to drive new growth initiatives, increased revenue and scale from the purchase of the PASCAL® line and expanded distribution network throughout Asia Pacific and key EMEA regions, we expect the partnership to help significantly increase the market penetration of Iridex’s industry leading retina products and innovative non-incisional glaucoma therapy,” Mr. Bruce concluded. Fourth Quarter 2020 Financial Results Revenue for the three months ended January 2, 2021 increased 5% to $12.3 million from $11.8 million during the same period of the prior year. The increase in revenue was driven primarily by growth in the Company’s retina business. Gross profit for the fourth quarter of 2020 increased to $5.6 million, or 45.4% gross margin, compared to $4.9 million, or 41.2% gross margin, in the same period of the prior year. Operating expenses for the fourth quarter of 2020 decreased 9% to $5.9 million compared to $6.5 million in the same period of the prior year. This is the result of ongoing efforts to reduce operating expenses in response to COVID-19-related temporary revenue reductions during 2020. Net Loss for the fourth quarter of 2020 was reduced to $179,000, compared to $1.6 million in the same period of the prior year. Net Loss on a per share basis was reduced to $0.01 versus $0.11 last year. Full Year 2020 Financial Results Revenue for the year ended January 2, 2021 decreased $7.1 million to $36.3 million from $43.4 million in 2019. The decrease was driven primarily by challenges associated with COVID-19. Gross profit for the full year 2020 was $15.6 million, or 42.8% gross margin, compared to $17.9 million, or 41.3% gross margin, during the prior year. Operating expenses for 2020 were reduced 18% to $22.1 million compared to $26.9 million in the prior year. This decrease is primarily from reduction in sales and marketing expenses during the COVID-19 slowdown in travel, tradeshows, and other sales and marketing activities. Net loss for 2020 was reduced to $6.3 million, compared $8.8 million in the prior year. Cash and cash equivalents were $11.6 million as of January 2, 2021. Guidance for Full Year 2021 Given the continuing uncertainty in product demand due to COVID-19, combined with variability introduced by the Topcon collaboration affecting revenue recognition, sales transition effects and integration costs for the PASCAL product line, Iridex cannot provide meaningful financial guidance for 2021 at this time. Webcast and Conference Call Information Iridex’s management team will host a conference call today beginning at 2:00 p.m. PT / 5:00 p.m. ET. Investors interested in listening to the conference call may do so by dialing (844) 707-0665 for domestic callers or (703) 326-3030 for international callers, using conference ID: 1137827. A live and archived webcast of the event will be available on the “Investors” section of the Company’s website at: www.Iridex.com. About Iridex Iridex is a worldwide leader in developing innovative and versatile laser-based medical systems, delivery devices and consumable instrumentation for the ophthalmology market. The Company’s proprietary MicroPulse® technology delivers a differentiated treatment that provides safe, effective, and proven treatment for targeted sight-threatening eye conditions. Iridex’s current product line is used for the treatment of glaucoma, diabetic macular edema and other retinal diseases. Iridex products are sold in the United States and Germany through a direct sales force and in more than 100 countries through a network of independent distributors. For more information, visit www.Iridex.com. Safe Harbor Statement This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Act of 1934, as amended, including those statements concerning the transactions described above. Such statements include those referring to the transaction described above and the benefits related thereto. These statements are not guarantees of future performance and actual results may differ materially from those described in these forward-looking statements as a result of a number of factors. Please see a detailed description of these and other risks contained in our Annual Report on Form 10-K for the fiscal year ended December 28, 2019, and Quarterly Reports on Form 10-Q for subsequent fiscal quarters, each of which was filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date and will not be updated. Investor Relations Contact Leigh Salvo (415) 937-5404 investors@Iridex.com host Mon, 22 Mar 2021 21:32:00 GMT f1397696-738c-4295-afcd-943feb885714:52 https://iridex.com:443/Default.aspx?tabid=59&articleType=ArticleView&articleId=51#Comments 0 https://iridex.com/DesktopModules/DnnForge%20-%20NewsArticles/RssComments.aspx?TabID=59&ModuleID=524&ArticleID=51 https://iridex.com:443/DesktopModules/DnnForge%20-%20NewsArticles/Tracking/Trackback.aspx?ArticleID=51&PortalID=0&TabID=59 https://iridex.com:443/Default.aspx?tabid=59&articleType=ArticleView&articleId=51 Mountain View, CA — March 10, 2021 — Iridex Corporation (NASDAQ: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, announced today that it has completed the previously announced transaction with Topcon Corporation. Under the terms of the agreements, Topcon Corporation and its affiliates have completed the $10 million equity investment in Iridex and the purchase of exclusive distribution rights to the Iridex products in Asia Pacific and key EMEA regions, and Iridex has completed the purchase of assets related to PASCAL® laser products. The total transaction results in a net amount of $19.5 million to Iridex. The transaction was announced on March 2, 2021. “This capital infusion allows Iridex to invest in our strategic growth initiatives,” said David Bruce, chief executive officer of Iridex,” enabling both our unique non-incisional glaucoma therapy products, and our newly broadened retina product line and distribution network, to ultimately benefit physicians and the patients they care for, worldwide. We appreciate the high-level commitment and investment Topcon has made in our company, and we look forward to a strong partnership.”About Topcon Corporation Topcon Corporation is headquartered in Tokyo Japan. A globally oriented business, Topcon is focused on developing solutions towards solving societal challenges in the mega-domains of healthcare, agriculture, and infrastructure. Revenue in fiscal 2019 was approximately $1.3 billion. Topcon Corporation (www.topcon.co.jp/en), founded in 1932, is traded on the Tokyo Stock Exchange (7732). Topcon Healthcare is a branded eyecare business of Topcon. Topcon Healthcare sees eye health differently. Our vision is to empower providers with smart and efficient technologies for enhanced patient care. Keeping pace with the ever-changing landscape of the healthcare industry, we offer the latest integrated solutions, including advanced multi-modal imaging, vendor-neutral data management, safe distancing, and ground-breaking remote diagnostic technology. https://topconhealthcare.com/us/ About IRIDEXIridex is a worldwide leader in developing innovative and versatile laser-based medical systems, delivery devices and consumable instrumentation for the ophthalmology market. The Company’s proprietary MicroPulse® technology delivers a differentiated treatment that provides safe, effective, and proven treatment for targeted sight-threatening eye conditions. Iridex’s current product line is used for the treatment of glaucoma, diabetic macular edema and other retinal diseases. Iridex products are sold in the United States and Germany through a direct sales force and in more than 100 countries through a network of independent distributors. For more information, visit www.iridex.com. Investor Relations ContactLeigh Salvo(415) 937-5404investors@iridex.comMedia ContactJamie Hall Pascale Communications, LLC.(724) 417-0167jamie@pascalecommunications.com host Fri, 12 Mar 2021 22:49:00 GMT f1397696-738c-4295-afcd-943feb885714:51 https://iridex.com:443/Default.aspx?tabid=59&articleType=ArticleView&articleId=50#Comments 0 https://iridex.com/DesktopModules/DnnForge%20-%20NewsArticles/RssComments.aspx?TabID=59&ModuleID=524&ArticleID=50 https://iridex.com:443/DesktopModules/DnnForge%20-%20NewsArticles/Tracking/Trackback.aspx?ArticleID=50&PortalID=0&TabID=59 https://iridex.com:443/Default.aspx?tabid=59&articleType=ArticleView&articleId=50 Transaction provides $19.5 million cash to Iridex, as two leaders join forces in glaucoma and retinal disease treatment Iridex to host a conference call presentation on March 2, 2021 at 2:00 p.m. PT/5:00 p.m. ET Mountain View, CA — March 2, 2021 — Iridex Corporation (NASDAQ: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, announced today that it has entered into a strategic collaboration with Topcon Corporation. Topcon is a Japanese-based manufacturer and distributor with approximately $1.3 billion in annual revenues, including $430 million from its eye care business. Highlights of the new strategic relationship include: The transaction nets $19.5 million of cash to Iridex, providing multiyear funding for strategic growth initiatives, particularly those designed to drive expanded market penetration of Iridex’s unique non-incisional glaucoma therapy products Topcon invests in Iridex by i) purchasing exclusive rights to distribute Iridex’s retina and glaucoma products in certain global markets, and ii) acquiring a common equity stake of approximately 10.4% in Iridex Iridex product portfolio to benefit from Topcon’s distribution strength in Asia Pacific and key EMEA markets, joining Topcon’s broad offering of diagnostic and treatment products for glaucoma and retina customers Iridex acquires Topcon’s PASCAL® product line, combining Iridex’ MicroPulse® technology with Topcon’s PASCAL® laser platform, resulting in a leading market share for retinal scanning laser products, plus greater scale to generate design, manufacturing and marketing efficiencies Terms of the Agreements The comprehensive collaboration between Iridex and Topcon includes three main agreements: an Exclusive Distribution Agreement, an Asset Purchase Agreement and an Equity Funding Agreement. Under the terms of these agreements, Topcon will acquire exclusive distribution of Iridex laser systems, delivery devices and disposable probes to be sold through its strong networks in Asia Pacific and key EMEA regions. Concurrently, Iridex will add Topcon’s PASCAL® systems to its U.S. direct sales and rest- of-world distribution network. Further, Iridex will acquire the design and manufacturing operation of Topcon’s PASCAL® product line. Finally, Topcon will purchase $10 million of Iridex common shares at a price of $6.18 per share. The net cash proceeds to Iridex of these transactions are expected to be approximately $19.5 million before offering expenses. About the partnership, David Bruce, CEO of Iridex, said, “We feel energized entering into this important alliance with Topcon that advances the strategic positions of both companies on multiple fronts. Joining Topcon’s comprehensive distribution network throughout Asia Pacific and key EMEA regions will help Iridex to significantly expand the market penetration of our marquee non-incisional glaucoma therapy. Topcon can further capitalize on its already-strong distribution network by adding our leading retina product portfolio to enhance the breadth of its ophthalmic system offerings. This alliance will enable both companies to benefit from the enhanced scale achieved by consolidating the design, manufacturing and distribution of two leaders in scanning laser retinal treatment. Finally, with $19 million in additional capital, Iridex has the resources to drive its multiyear growth programs.” “We sought this alliance with Iridex to achieve significant benefits to our operating and distribution efforts. As leaders and innovators in advancing the treatment options for eyesight threatening diseases, we recognize a great opportunity to bring our strengths together,” said Fumio Ohue, Managing Executive Officer of Topcon’s Eye Care Business. “We are excited to bring Iridex’s retina and glaucoma therapy products to our expansive customer base throughout Asia Pacific and key Europe, Middle East and Africa markets. This alliance with Iridex is one of the major initiatives which Topcon will offer with our ‘Shared Care’ program. We are confident that combining our new product design and development efforts will enhance our existing and future products in both retina and glaucoma.” Mr. Bruce concluded, “In line with our goal of ensuring the long-term adoption of our laser-based MicroPulse TLT procedure in the marketplace, we are gratified with the high-level commitment Topcon has made to our platform, and we look forward to a strong partnership that is beneficial for patients and eye care specialists around the world for years to come.” Conference Call Details In conjunction with the announcement, the companies’ management team will host a conference call today, March 2, 2021, beginning at 2:00 p.m. PT / 5:00 p.m. ET. Investors interested in listening to the conference call may do so by dialing (844) 707-0665 for domestic callers or (703) 326-3030 for international callers, using conference ID: 5157177. A live and archived webcast of the event will be available on the “Investors” section of the Iridex website at: www.Iridex.com. About Topcon Corporation Topcon Corporation is headquartered in Tokyo Japan. A globally oriented business, Topcon is focused on developing solutions towards solving societal challenges in the mega-domains of healthcare, agriculture, and infrastructure. Revenue in fiscal 2019 was approximately $1.3 billion. Topcon Corporation (www.topcon.co.jp/en), founded in 1932, is traded on the Tokyo Stock Exchange (7732). Topcon Healthcare is a branded eyecare business of Topcon. Topcon Healthcare sees eye health differently. Our vision is to empower providers with smart and efficient technologies for enhanced patient care. Keeping pace with the ever-changing landscape of the healthcare industry, we offer the latest integrated solutions, including advanced multi-modal imaging, vendor-neutral data management, safe distancing, and ground-breaking remote diagnostic technology. https://topconhealthcare.com/us/ About Iridex Iridex is a worldwide leader in developing innovative and versatile laser-based medical systems, delivery devices and consumable instrumentation for the ophthalmology market. The Company’s proprietary MicroPulse® technology delivers a differentiated treatment that provides safe, effective, and proven treatment for targeted sight-threatening eye conditions. Iridex’s current product line is used for the treatment of glaucoma, diabetic macular edema and other retinal diseases. Iridex products are sold in the United States and Germany through a direct sales force and in more than 100 countries through a network of independent distributors. For more information, visit www.Iridex.com. Safe Harbor Statement This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Act of 1934, as amended, including those statements concerning the transactions described above. Such statements include those referring to the transaction described above and the benefits related thereto. These statements are not guarantees of future performance and actual results may differ materially from those described in these forward-looking statements as a result of a number of factors. Please see a detailed description of these and other risks contained in our Annual Report on Form 10-K for the fiscal year ended December 28, 2019, and Quarterly Reports on Form 10-Q for subsequent fiscal quarters, each of which was filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date and will not be updated. Investor Relations Contact Leigh Salvo (415) 937-5404 investors@Iridex.com Media Contact Jamie Hall Pascale Communications, LLC. (724) 417-0167 jamie@pascalecommunications.com host Tue, 02 Mar 2021 21:10:00 GMT f1397696-738c-4295-afcd-943feb885714:50 https://iridex.com:443/Default.aspx?tabid=59&articleType=ArticleView&articleId=49#Comments 0 https://iridex.com/DesktopModules/DnnForge%20-%20NewsArticles/RssComments.aspx?TabID=59&ModuleID=524&ArticleID=49 https://iridex.com:443/DesktopModules/DnnForge%20-%20NewsArticles/Tracking/Trackback.aspx?ArticleID=49&PortalID=0&TabID=59 https://iridex.com:443/Default.aspx?tabid=59&articleType=ArticleView&articleId=49 MOUNTAIN VIEW, Calif., January 11, 2021 -- Iridex Corporation (Nasdaq: IRIX) today provided preliminary unaudited operational and financial results for the fourth quarter and full year ended January 2, 2021. Fourth Quarter 2020 Total revenue expected to be $12.2 million to $12.4 million, versus $11.8 million in the fourth quarter of 2019 Cash and cash equivalents of approximately $11.6 million as of January 2, 2021, representing a net cash burn of $0.3 million in the fourth quarter, and $1.0 million for the full year 2020 Sold 13,500 Cyclo G6® probes in the fourth quarter of 2020, slightly above the prior year quarter U.S. sales of Cyclo G6 probes increased by 8% compared to prior year fourth quarter, and set a new quarterly record, despite the continuing impacts of COVID-19 restrictions Sold 56 Cyclo G6 Glaucoma Laser Systems in the fourth quarter, compared to 105 in the prior year quarter, reflecting COVID-19 impact on capital equipment purchases outside the US, and the Company’s shift to focusing on glaucoma procedure volumes rather than systems placements Full Year 2020 Total revenue expected to be $36.2 million to $36.4 million, approximately 16% below fiscal year 2019 revenue of $43.4 million. Sold 45,800 Cyclo G6 probes, compared to 51,500 in the prior year, reflecting the significant midyear impact of COVID 19 on ophthalmic procedure volume Sold 173 Cyclo G6 Glaucoma Laser Systems compared to 350 in the prior year reflecting a shift in sales focus towards probe adoption and the impacts of COVID-19 on capital purchase volumes worldwide. “As with many other companies, our business was impacted by COVID-19 during 2020, but our strong recovery and improving momentum is evident from the fourth quarter results,” said David I. Bruce, President and CEO of Iridex. “Total revenue and Cyclo G6 probe sales exceeded the pre-pandemic levels from the prior year quarter. This was achieved simultaneously with highly focused expense management, resulting in net cash burn of only $1.0 million for the entire year.” Bruce continued, “Product improvements contributed to the strength of our business in both Glaucoma and Retina segments. Release of an improved MicroPulse P3 probe in late 2019 helped drive increased adoption in 2020, leading to quarterly records for Cyclo G6 probes sales in both the third and fourth quarters. Strength in Retina product sales reflected our improved competitive position thanks to several product enhancements released in 2020, including the introduction of the LIO Plus, a Laser Indirect Ophthalmoscope (LIO). Our momentum is expected to continue in the new year, including the launch of a new 810 wavelength laser, the first in a family of new lasers offering substantial savings in manufacturing costs and gross margin improvement,” concluded Bruce. These preliminary results are based on management's initial analysis of operations for the quarter and year ended January 2, 2021 and are subject to completion of the Company’s year-end financial reporting processes, further internal review and audit by the Company's external auditors. About Iridex Iridex Corporation is a worldwide leader in developing, manufacturing, and marketing innovative and versatile laser-based medical systems, delivery devices and consumable instrumentation for the ophthalmology market. The Company’s proprietary MicroPulse® technology delivers a differentiated treatment that provides safe, effective, and proven treatment for targeted sight-threatening eye conditions. Iridex’s current product line is used for the treatment of glaucoma and diabetic macular edema (DME) and other retinal diseases. Iridex products are sold in the United States through a direct sales force and internationally primarily through a network of independent distributors into more than 100 countries. For further information, visit the Iridex website at www.Iridex.com. Safe Harbor Statement This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Act of 1934, as amended, including those statements concerning the demand for and utilization of the Company's products, expectations for growth, and the Company’s unaudited results for the fourth quarter and fiscal year 2020. These statements are not guarantees of future performance and actual results may differ materially from those described in these forward-looking statements as a result of a number of factors. Please see a detailed description of these and other risks contained in our Annual Report on Form 10-K for the fiscal year ended December 28, 2019, and Quarterly Reports on Form 10-Q for subsequent fiscal quarters, each of which was filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date and will not be updated. Investor Relations Contact Leigh Salvo (415) 937-5404 investors@Iridex.com host Mon, 11 Jan 2021 22:38:00 GMT f1397696-738c-4295-afcd-943feb885714:49 https://iridex.com:443/Default.aspx?tabid=59&articleType=ArticleView&articleId=48#Comments 0 https://iridex.com/DesktopModules/DnnForge%20-%20NewsArticles/RssComments.aspx?TabID=59&ModuleID=524&ArticleID=48 https://iridex.com:443/DesktopModules/DnnForge%20-%20NewsArticles/Tracking/Trackback.aspx?ArticleID=48&PortalID=0&TabID=59 https://iridex.com:443/Default.aspx?tabid=59&articleType=ArticleView&articleId=48 • Guidelines provide recommendations on the diagnosis and management of glaucoma within the EU • Nine MicroPulse TLT studies presented at the annual EGS meeting supporting its safety, effectiveness, and versatility in the treatment of glaucoma Mountain View, CA — December 22, 2020 — Iridex Corporation (NASDAQ: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, reports that MicroPulse Transscleral Laser Therapy (TLT), which is performed using the Iridex Cyclo G6® Laser System and MicroPulse P3® Delivery Device, has been included in the European Glaucoma Society (EGS) Terminology and Guidelines for Glaucoma. The EGS guidelines represent recommendations on the diagnosis and management of glaucoma to standardize practice within the European Union. The new guidelines, the Society’s 5th edition, were presented at the Annual EGS Meeting on December 12-13, 2020. “We are very encouraged with the broadening recognition of MicroPulse TLT in the ophthalmic community,” said David Bruce, CEO, Iridex. “Inclusion in the EGS guidelines plus nine papers presented in the Society’s meeting shows the growing adoption of this effective non-incisional therapy for the management of glaucoma disease.” MicroPulse TLT is a non-incisional procedure that substantially reduces intraocular pressure (IOP) for a broad range of glaucoma types and severity. The procedure can be used for primary open-angle, closed-angle, and refractory glaucoma. It’s a repeatable treatment option that can be performed before, during, or after other glaucoma interventions. More than 140,000 patients have been treated with MicroPulse TLT in top ophthalmic hospitals around the globe. Also presented at the EGS meeting, were nine MicroPulse TLT studies. These studies were conducted in several countries which exemplify the continued global expansion of MicroPulse TLT. Featured studies included: P248: MicroPulse Transscleral Cyclophotocoagulation: Step by Step; Rita Basto, et al. (Poland) This study represents a 6-month retrospective review of glaucoma patients (38 eyes) treated with MicroPulse TLT. The percentage of IOP reduction was 43.4 ± 16.2% (8.9% - 70.6%). A success rate (defined as >20% IOP reduction and IOP ≤ 21 mmHg) was obtained in 81.6% of cases with no records of serious complications. The authors concluded that MicroPulse TLT is easily performed, can be repeated with good results, is an efficient and safe strategy to reduce IOP, and can be used in a wide spectrum of glaucoma disease. P350: Use of MicroPulse Transscleral Cyclophotocoagulation in Glaucoma Associated with Penetrating Keratoplasty or KPRO; Consuelo Gajardo Menzel, et al. (Peru) The authors presented 1-year follow-up of MicroPulse TLT in glaucomatous patients with corneal grafts. Patients’ IOP was reduced by an average of 50%, and the authors concluded that MicroPulse TLT in patients with corneal transplants is effective and safe. P359: Microimpulse Cyclophotocoagulation in Combined Neovascular Glaucoma Treatment; Nazir Khodzhaev, et al. (Russia) This study evaluated a combined treatment of anti-vascular endothelial growth factors (VEGF) injections and MicroPulse TLT in 15 patients (15 eyes) with secondary neovascular glaucoma (NVG). Initial outcomes demonstrated an IOP reduction of approximately 26%, with a reduction in drops from 3.5 to 2.7, concluding that anti-VEGF and MicroPulse TLT are a safe and effective treatment in NVG patients. 430: Topical Anesthesia for Diode Transscleral MicroPulse Cyclophototherapy; Maria Cecilia Aquino, et al. (Singapore) This study evaluated the use of topical anesthesia and oral paracetamol in a prospective case series of 22 patients receiving MicroPulse TLT. Although a majority of patients experienced moderate pain during treatment, all patients tolerated the entire treatment lasting for 100 seconds without additional peribulbar anesthesia. The post-operative pain in the immediate 24-hours after treatment was unremarkable requiring no oral analgesic medications. Other studies presented: P043: MicroPulse Transscleral Laser in Children - The Auckland and Singapore Experience; Marcus Tan, et al. (New Zealand) P211: Short-term Efficacy and Safety of MicroPulse Transscleral Cyclophotocoagulation in Asian Glaucoma Patients; Mi Sun Sung, et al. (South Korea) P226: Mid-Term Results of Micro-Pulse Transscleral Cyclophotocoagulation with Diode Laser on Treatment of Glaucoma: A Retrospective Analysis; Guido Barosco et al. (Italy) P245: Outcomes of MicroPulse transscleral cyclophotocoagulation in Patients with Glaucoma – A Case Series; Wojciech Maruszczyk, et al. (Poland) P485: A Modified MicroPulse Transscleral Cyclophototherapy technique for the Treatment of Refractory Glaucoma; Victor Teck Koh, et al. (Singapore) More information can be found at: www.Iridex.com/egs About Iridex Iridex is a worldwide leader in developing innovative and versatile laser-based medical systems, delivery devices and consumable instrumentation for the ophthalmology market. The Company’s proprietary MicroPulse® technology delivers a differentiated treatment that provides safe, effective, and proven treatment for targeted sight-threatening eye conditions. Iridex’s current product line is used for the treatment of glaucoma, diabetic macular edema and other retinal diseases. Iridex products are sold in the United States and Germany through a direct sales force and in more than 100 countries through a network of independent distributors. For more information, visit www.Iridex.com/MicroPulseP3. Investor Relations Contact Leigh Salvo (415) 937-5404 investors@Iridex.com Media Contact Jamie Hall Pascale Communications, LLC. (724) 417-0167 jamie@pascalecommunications.com host Wed, 23 Dec 2020 00:20:00 GMT f1397696-738c-4295-afcd-943feb885714:48 https://iridex.com:443/Default.aspx?tabid=59&articleType=ArticleView&articleId=47#Comments 0 https://iridex.com/DesktopModules/DnnForge%20-%20NewsArticles/RssComments.aspx?TabID=59&ModuleID=524&ArticleID=47 https://iridex.com:443/DesktopModules/DnnForge%20-%20NewsArticles/Tracking/Trackback.aspx?ArticleID=47&PortalID=0&TabID=59 https://iridex.com:443/Default.aspx?tabid=59&articleType=ArticleView&articleId=47 To our valued customers and partners, As the COVID-19 pandemic continues, our thoughts go out to those who have been impacted. Our priority at Iridex is to support our customers, their patients and our employees. We are reacting to the rapidly changing business realities due to the COVID-19 pandemic, with the goals of keeping our ecosystem safe and by adjusting our activities to maintain support of critical production, supply chain and clinical support for our customers. We want to assure all Iridex partners that our sales and clinical teams, as well as our customer service representatives, are available to assist you. We are not currently expecting delays in our supply chain or distribution and are making technical arrangements to support you clinically. At Iridex we are committed to providing our clinical partners the very best training and support. Due to many facilities opting to restrict procedures and operating room access to essential personnel only, we have developed a web page (www.Iridex.com/training) to provide you clinical and technical information and resources on our products. This web page will also help with your preparation to perform MicroPulse® Transscleral Laser Therapy with the MicroPulse P3® Device. Our national and international Area Sales Managers and Clinical Application Specialists as well as our distribution partners are available via video conferencing and facetime to answer all surgical and procedural questions and concerns. We are here to help you. If there is something in particular that you need, please contact your Iridex representative, send us an email at info@Iridex.com, or visit our contact us page (www.Iridex.com/contact). We will remain diligent in monitoring new developments, adjust where necessary, and do our part to manage through this pandemic. Stay safe and healthy. As we go forward together, please know that we value your questions, ideas and feedback. Sincerely David Bruce CEO, Iridex host Wed, 25 Mar 2020 16:17:00 GMT f1397696-738c-4295-afcd-943feb885714:47 https://iridex.com:443/Default.aspx?tabid=59&articleType=ArticleView&articleId=46#Comments 0 https://iridex.com/DesktopModules/DnnForge%20-%20NewsArticles/RssComments.aspx?TabID=59&ModuleID=524&ArticleID=46 https://iridex.com:443/DesktopModules/DnnForge%20-%20NewsArticles/Tracking/Trackback.aspx?ArticleID=46&PortalID=0&TabID=59 https://iridex.com:443/Default.aspx?tabid=59&articleType=ArticleView&articleId=46 Mountain View, Calif. September 12, 2019 -- Iridex Corporation (NASDAQ: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, announced today that its patented MicroPulse® laser therapy will be featured prominently in research presented at the 2019 European Society of Cataract & Refractive Surgeons (ESCRS) meeting, to be held in Paris, France on Friday, September 13 through Wednesday, September 18. MicroPulse Transscleral Laser Therapy (TLT) is a non-incisional, laser-based procedure used to treat a wide range of glaucoma cases. More than 100,000 procedures have been performed in 60 countries since 2015. “MicroPulse Transscleral Cyclophotocoagulation is changing the way glaucoma specialist address glaucoma, and the plethora of abstracts showcasing this procedure at ESCRS offers additional proof that its safety profile continues to validate the favorable results of non-incisional glaucoma treatment,” said Dr. K. Sheng Lim, Head of the Glaucoma Service at St. Thomas’ Hospital and Associate Professor, Faculty of Life Sciences and Medicine at King’s College London. At ESCRS 2019, there will be several opportunities for attendees to learn about the safety, efficacy, and clinical versatility of MicroPulse TLT for glaucoma within the ESCRS program, at a wet lab, a symposium, and at the Iridex booth (#C125). Abstract Presentations: Efficacy and safety of MicroPulse cyclophotocoagulation for patients with ocular hypertension and glaucoma Q. Kaba, E. Tam, S. Somani, D. Yuen Presented Poster Session, Glaucoma 1 Sunday, September 15 at 9:40 AM local time Early results of phacoemulsification combined with MicroPulse cyclodiode laser in patients with glaucoma: efficacy and safety A. Daas, A. Nagar, H. Ho, A. Amon, I. Versi, K. Gadhvi, S. Lim Presented Poster Session, Glaucoma 1 Sunday, September 15 at 9:50 AM local time Comparative study of the safety and efficacy of two techniques of diode laser transscleral cyclophotocoagulation for refractory glaucoma A. Matsou, M. Dermenoudi, A. Tzamalis, E. Anastasopoulos Presented Poster Session, Glaucoma II Sunday, September 15 at 3:10 PM local time Long-term clinical outcomes of MicroPulse transscleral cyclophotocoagulation in open-angle glaucoma B. Basarir, C. Altan, B. Solmaz, I. Pasaoglu, N. Alagoz, T. Yasar Presented Poster Session, Glaucoma 1 Sunday, September 15 at 3:35 PM local time Safety and efficacy of combined transscleral MicroPulse diode laser cyclocoagulation with phacoemulsification and intraocular lens implantation O. Parkhomenko, G. Parkhomenko, O. Parkhomenko, A. Kovalenko E-Poster: Combined Cataract Surgery Techniques MicroPulse transscleral cyclophotocoagulation for the management of glaucoma after silicone oil removal in vitrectomized eyes A. Samir, A. AlQarni, M. Almalis E-Poster: Glaucoma Advancing cataract and refractive surgical and therapeutic applications through new ophthalmic laser technology S. Rowen, A. Hipsley, L. Gualdi, S. Shah, R. Ang, M. Jackson E-Poster: Presbyopia Clinical Symposium: Lunch Symposium: Rethinking Glaucoma Care with Non-incisional and Versatile MicroPulse Transscleral Photocoagulation Sunday, September 15 at 1:00 PM local time | Room South 6 Moderated by Ziad Khoueir, MD Presentations include: Scientific rationale and clinical application of MicroPulse Transscleral Cyclophotocoagulation. K. Sheng Lim, MD 2-Year Follow-up on the Structural and Functional Stability of Glaucoma post-MicroPulse TSCPC. Syril K. Dorairaj, MD MicroPulse Transscleral Cyclophotocoagulation: When I (must) think about it. Prof. Philippe Denis, MD MicroPulse TSCPC in the Netherlands: clinical cases and various patients’ profiles. Ronald de Crom, MD Optimizing MicroPulse TSCPC for multiple glaucoma types and post-operative management. Nathan Radcliffe, MD More details about this symposium available at www.Iridex.com/escrs. MicroPulse Experts at ESCRS: At ESCRS 2019, Iridex will host glaucoma specialists at its booth (#C125) to conduct 1-on-1 conversations with attendees, sharing their experience using non-incisional MicroPulse transscleral laser therapy for glaucoma. This provides an excellent opportunity for attendees to ask them direct questions about patient selection, technique, outcomes, their research, and the safety and efficacy of the procedure. The list of guest speakers and schedule is available at www.Iridex.com/escrs Wet Lab Sessions: A wet lab that is part of the ESCRS program will feature Iridex’s Cyclo G6 Laser that is needed to perform non-incisional glaucoma treatment. Advanced registration is required to participate.Visit the ESCRS website for more information. “Modern MIGS techniques not using implants.” ESCRS Surgical Skills Training Course Session 1: Monday, September 16 from 1:00-4:00 PM local time Session 2: Monday, September 16 from 4:30-7:30 PM local time About Iridex Iridex is a worldwide leader in developing innovative and versatile laser-based medical systems, delivery devices and consumable instrumentation for the ophthalmology market. The Company’s proprietary MicroPulse® technology delivers a differentiated treatment that provides safe, effective, and proven treatment for targeted sight-threatening eye conditions. Iridex’s current product line is used for the treatment of glaucoma, diabetic macular edema (DME) and other retinal diseases. Iridex products are sold in the United States and Germany through a direct sales force and in more than 100 countries through a network of 60 independent distributors. For more information, visit http://www.Iridex.com. Investor Relations Contact: Leigh Salvo (415) 937-5404 investors@Iridex.com Media Contact: Jamie Hall Pascale Communications, LLC. (724) 417-0167 pr@Iridex.com host Thu, 12 Sep 2019 00:32:00 GMT f1397696-738c-4295-afcd-943feb885714:46 https://iridex.com:443/Default.aspx?tabid=59&articleType=ArticleView&articleId=45#Comments 0 https://iridex.com/DesktopModules/DnnForge%20-%20NewsArticles/RssComments.aspx?TabID=59&ModuleID=524&ArticleID=45 https://iridex.com:443/DesktopModules/DnnForge%20-%20NewsArticles/Tracking/Trackback.aspx?ArticleID=45&PortalID=0&TabID=59 https://iridex.com:443/Default.aspx?tabid=59&articleType=ArticleView&articleId=45 MOUNTAIN VIEW, Calif., May 21, 2019 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, announced the appointment of David Bruce to be the company’s President and Chief Executive Officer, effective today. “We are pleased to appoint David Bruce to the role of President and CEO,” said Dr. Ruediger Naumann-Etienne, Lead Independent Director at Iridex. “David brings substantial experience leading successful commercial and market penetration strategies at several medical device companies, and he has been a member of Iridex’s Board of Directors for over a year. He is well prepared to expand worldwide sales and marketing execution for the Cyclo G6® Glaucoma Laser and Probe System and to build on Iridex’s leading retina laser position in the global market. We look forward to David’s leadership driving the company to significant growth,” Naumann-Etienne continued. Mr. Bruce has been a member of Iridex’s board of directors since April, 2018 and has held several CEO and leadership positions in both public and private medical device growth-stage companies. He served as CEO and Director of Arstasis, an arterial access device company, CEO and Director of EP MedSystems, which was acquired by St. Jude Medical, and interim CEO and Director of Patient Safety Technologies. He was also General Manager of the AcuNav Catheter Business for Siemens Medical Solutions, and COO for Catheter Robotics, a privately held, pre-commercial remote catheter systems company. He holds a MBA from the Wharton School at the University of Pennsylvania and a BS in Mechanical Engineering from the University of California, Berkeley. “I am excited to lead Iridex in capitalizing on our MicroPulse® therapy for glaucoma patients,” said David Bruce. “This proven technology, with over 120,000 procedures performed by hundreds of ophthalmologists worldwide and a rapidly-expanding body of clinical data that demonstrate its efficacy, low risk and cost advantages for reduction of intraocular pressures, deserves a much greater role treating the large glaucoma patient population worldwide. Our business model combines proprietary laser systems with disposable delivery probes creating a significant growth and recurring revenue opportunity through broader adoption in the ophthalmology community. Coupling this with Iridex’s leadership position in the retina laser market – with its own growth opportunities using MicroPulse technology – creates a platform for the creation of significant shareholder value. I am pleased to join the Iridex team to focus on growing the company’s revenue and achieving our value potential.” Dr. Naumann-Etienne expressed his appreciation to outgoing CEO, William M. Moore, “We thank Will for his leadership and contributions over the past six years in Iridex’s development and launch of this novel glaucoma therapy, positioning the company for the exciting growth opportunities ahead.” About Iridex Iridex Corporation is a worldwide leader in developing, manufacturing, and marketing innovative and versatile laser-based medical systems, delivery devices and consumable instrumentation for the ophthalmology market. The Company’s proprietary MicroPulse® technology delivers a differentiated treatment that provides safe, effective, and proven treatment for targeted sight-threatening eye conditions. Iridex’s current product line is used for the treatment of glaucoma, diabetic macular edema (DME) and other retinal diseases. Iridex products are sold in the United States through a direct sales force and internationally primarily through a network of independent distributors into more than 100 countries. For further information, visit the Iridex website at http://www.Iridex.com. Safe Harbor Statement This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Act of 1934, as amended, including those statements concerning the future demand, utilization and order levels for the Company's products, plans to introduce new products, and the Company’s guidance for fiscal 2019 and future financial results. These statements are not guarantees of future performance and actual results may differ materially from those described in these forward-looking statements as a result of a number of factors. Please see a detailed description of these and other risks contained in our Annual Report on Form 10-K for the fiscal year ended December 30, 2017, and Quarterly Reports on Form 10-Q for subsequent fiscal quarters, each of which was filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date and will not be updated. Investor Relations Contact: Leigh Salvo 415.937.5404 investors@Iridex.com host Tue, 21 May 2019 19:23:00 GMT f1397696-738c-4295-afcd-943feb885714:45 https://iridex.com:443/Default.aspx?tabid=59&articleType=ArticleView&articleId=44#Comments 0 https://iridex.com/DesktopModules/DnnForge%20-%20NewsArticles/RssComments.aspx?TabID=59&ModuleID=524&ArticleID=44 https://iridex.com:443/DesktopModules/DnnForge%20-%20NewsArticles/Tracking/Trackback.aspx?ArticleID=44&PortalID=0&TabID=59 https://iridex.com:443/Default.aspx?tabid=59&articleType=ArticleView&articleId=44 Mountain View, Calif. April 29, 2019 -- Iridex Corporation (NASDAQ: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, announced today that its patented MicroPulse® technology played a pivotal role in research presented at the 2019 Association for Research in Vision & Ophthalmology (ARVO) and American Society of Cataract & Refractive Surgeons (ASCRS) meetings, to be held in Vancouver, British Columbia, and San Diego, CA, respectively. At these annual meetings, there will be 20 scientific presentations on MicroPulse laser therapy that utilize Iridex’s Cyclo G6® Glaucoma Laser and MicroPulse P3® Delivery Device for treating multiple types of glaucoma, and Iridex’s IQ family of laser consoles for treating a variety of retinal disorders. This scientific data, and data presented at the American Glaucoma Society and World Glaucoma Congress meetings earlier in 2019, brings the total of Iridex-related data sets to approximately 40, demonstrating an increase in available, efficacious data for MicroPulse technology. "There is considerable clinical value in non-invasive procedures that lower intraocular pressure without placing activity restriction on the patient postoperatively," commented Jella An, MD, Director of Glaucoma Service, University of Missouri. "With its strong safety and efficacy profile, MicroPulse transscleral cyclophotocoagulation (MP-TSCPC) offers glaucoma specialists compelling options for treating patients who don't respond to medication alone,” commented Dr. An “I am looking forward to sharing how the research I have conducted alongside fellow glaucoma specialists continues to validate MP-TSCPC in clinical practice.” “As one of the most influential pioneers in ophthalmic laser therapy, we are thrilled to see our MicroPulse technology continue our legacy of innovation and quality in the market,” said William Moore, Chief Executive Officer of Iridex. “MicroPulse technology gives physicians the control and results they need when managing some of their patients’ most serious glaucoma and retinal conditions. We’re honored to be included in important research driving the future of glaucoma and retina care.” At the ARVO and ASCRS meetings, there are several opportunities for attendees to join physician presentations and Iridex-sponsored events to learn how to incorporate MicroPulse laser therapy into clinical practice using our Cyclo G6 Glaucoma Laser and MicroPulse P3 Delivery Device. Noteworthy Data Presented at ARVO Several studies presented at ARVO demonstrate the short- and long-term safety and efficacy of MicroPulse laser treatment for multiple types of glaucoma, including open-angle glaucoma and neovascular glaucoma, and for retinal conditions. These studies, while focusing on a wide range of clinical topics, further validate MicroPulse laser therapy as a safe, effective, and versatile treatment option for multiple serious ophthalmic conditions. Key presentations include: BO174: Efficacy of MicroPulse Laser Trabeculoplasty in Open Angle Glaucoma Clemente A, et.al. Sunday, April 28, 2019 | 1:00 – 2:45 PM | West Exhibition Hall BO175: Post-operative one-hour intraocular pressure spikes and long term pressure efficacy in micropulse laser trabeculoplasty (MLT) vs selective laser trabeculoplasty (SLT) Giovingo M, et. al. Sunday, April 28, 2019 | 1:00 – 2:45 PM | West Exhibition Hall BO176: Efficacy and safety of transscleral micropulsed laser in the treatment of glaucoma refractory to treatment Delgadillo L, et. al. Sunday, April 28, 2019 | 1:00 – 2:45 PM | West Exhibition Hall BO177: Short-term outcomes of MicroPulse Trans-scleral Cyclophotocoagulation in Korean patients Chung J. Sunday, April 28, 2019 | 1:00 – 2:45 PM | West Exhibition Hall BO178: MicroPulse Transscleral Cyclophotocoagulation in Refractory Glaucoma. 6 month follow-up Del Hierro C., et. al. Sunday, April 28, 2019 | 1:00 – 2:45 PM | West Exhibition Hall BO180: Outcomes of MicroPulse Cyclophotocoagulation in Adult Glaucoma Patients Grisham E., et. al. Sunday, April 28, 2019 | 1:00 – 2:45 PM | West Exhibition Hall BO181: The Efficacy and Safety of MicroPulse Photocyclophotocoagulation in the Treatment of Refractory Advanced Pediatric Glaucomas Reiser J B. Sunday, April 28, 2019 | 1:00 – 2:45 PM | West Exhibition Hall BO182: Three-Year Retrospective Study of Treatment with Micropulse Cyclophotocoagulation as a Primary Procedure for Neovascular Glaucoma Giovingo M, et. al. Sunday, April 28, 2019 | 1:00 PM – 2:45 PM | West Exhibition Hall BO183: Intraocular pressure reduction profile in patients with refractory glaucoma submitted to micropulse transscleral cyclophotocoagulation  Dorairaj S, et. al. Sunday, April 28, 2019 | 1:00 – 2:45 PM | West Exhibition Hall BO184: Pars plicata versus pars plana application of micropulse transscleral cyclophotocoagulation Waibel A. Sunday, April 28, 2019 | 1:00 – 2:45 PM | West Exhibition Hall Presentation Number 2825: Microscope Real-time Video, High- resolution OCT & Histopathology to Assess How Transcleral Micropulse Laser Affects the Sclera, Ciliary Body, Muscle, Secretory Epithelium, Suprachoroidal Space & Aqueous Outflow System Johnstone M. Tuesday, April 30, 2019 | 9:15 – 9:30 AM | West 212-214 Presentation Number 2826: Clinical outcomes of micropulse transscleral cyclophotocoagulation in post-keratoplasty patients Kang J. Tuesday, April 30, 2019 | 9:30 – 9:45 AM | West 212-214 B0312: Outcomes of Micropulse Transscleral Cyclophotocoagulation in a Hispanic Population Vincent L., et. Al. Tuesday, April 30, 2019 | 11:45 – 1:30 PM | West Exhibition Hall MicroPulse Laser Therapy for Retina BO189: Comparing intravitreal bevacizumab, sub threshold macular laser (STML) and intravitreal dexamethasone implant (0.7mg) in the initial treatment of diabetic macular edema (DME) in a resident led clinic Mughal M., et. al. Tuesday, April 30, 2019 | 11:45 – 1:30 PM | West Exhibition Hall A0215: Subthreshold laser treatment following full thickness macular hole surgery Stanzel B. Thursday, May 2, 2019 | 3:00 – 4:45 PM | West Exhibition Hall Presentation Number 3861: Subthreshold MicroPulse Laser Treatment of Human Diabetic Macular Edema: The Role of Müller Cells, Retinal Pigment Epithelium and the Inflammatory Cascade Midena E. Tuesday, April 30, 2019 | 3:00 – 3:15 PM | East Ballroom B Noteworthy Data Presented at ASCRS Outcomes of MicroPulse Transscleral Cyclophotocoagulation in Keratoplasty Eyes Feng M., Price M., Price W. Sunday, May 05, 2019 | 04:02 PM - 04:07 PM |SDCC - Upper Level, Room 7A A study by Matthew Feng et. al., evaluates outcomes of MicroPulse transscleral cyclophotocoagulation for intraocular pressure control in keratoplasty eyes, finding that MicroPulse laser treatment was a non-invasive alternative to glaucoma filtration surgery for IOP reduction in keratoplasty eyes. Note: This study was published in March in the journal Cornea 2019;38:542–545. Iridex Events at ASCRS Eye care professionals interested in learning about Iridex MicroPulse technology are encouraged to attend Iridex events being held at the 2019 ASCRS congress, including: MicroPulse TSCPC as Treatment for Failed MIGS Procedures Sunday, May 5 (7:15 – 8:30 AM) at the Marriot Marquis Marina In this educational breakfast, learn how innovative clinicians Jella An, MD (MU Health Care) and Ahad Mahootchi, MD (The Eye Clinic of Florida) are using the Iridex Cyclo G6 laser to treat uncontrolled glaucoma patients. Discover their specific cases, patient selection, clinical evidence, and outcomes. Register at Iridex.com/ascrs or events@Iridex.com MicroPulse TSCPC: Meet the Experts Throughout the conference at Iridex Booth #3129 Throughout the 2019 ASCRS conference, Iridex will host a series of expert lectures on the Cyclo G6 laser’s use in clinical practice. Experienced ophthalmologists, including Michael Giovingo, MD (Cook County Health & Hospital), Shan Lin, MD (Glaucoma Center of San Francisco) and Ian P. Conner, MD PhD (UPMC) share their clinical case studies and insights in casual one-on-one conversations with audience participants. See the full list of attendees and register at Iridex.com/ascrs or events@Iridex.com About Iridex Iridex is a worldwide leader in developing innovative and versatile laser-based medical systems, delivery devices and consumable instrumentation for the ophthalmology market. The Company’s proprietary MicroPulse® technology delivers a differentiated treatment that provides safe, effective, and proven treatment for targeted sight-threatening eye conditions. Iridex’s current product line is used for the treatment of glaucoma, diabetic macular edema (DME) and other retinal diseases. Iridex products are sold in the United States and Germany through a direct sales force and in more than 100 countries through a network of independent distributors. For more information, visit http://www.Iridex.com. Investor Relations Contact: Leigh Salvo (415) 937-5404 investors@Iridex.com Media Contact: Jamie Hall Pascale Communications, LLC. (724) 417-0167 pr@Iridex.com host Mon, 29 Apr 2019 21:56:00 GMT f1397696-738c-4295-afcd-943feb885714:44 https://iridex.com:443/Default.aspx?tabid=59&articleType=ArticleView&articleId=43#Comments 0 https://iridex.com/DesktopModules/DnnForge%20-%20NewsArticles/RssComments.aspx?TabID=59&ModuleID=524&ArticleID=43 https://iridex.com:443/DesktopModules/DnnForge%20-%20NewsArticles/Tracking/Trackback.aspx?ArticleID=43&PortalID=0&TabID=59 https://iridex.com:443/Default.aspx?tabid=59&articleType=ArticleView&articleId=43 Mountain View, Calif., April 18, 2019— Iridex Corporation (Nasdaq: IRIX) today announced the Company will release financial results for the first quarter of 2019 after the close of trading on Thursday, May 2, 2019. The Company’s management team will host a corresponding conference call beginning at 2:00 p.m. PT / 5:00 p.m. ET. Investors interested in listening to the conference call may do so by dialing (844) 707-0665 for domestic callers or (703) 326-3030 for international callers, using conference ID: 7287797. A live and archived webcast of the event will be available on the “Investors” section of the Company’s website at: www.Iridex.com. A telephone replay will also be available beginning Thursday, March 2, 2019 through Friday, May 3, 2019 by dialing (855) 859-2056 for domestic callers or (404) 537-3406 for international callers, using conference ID: 7287797. About Iridex Iridex is a worldwide leader in developing, manufacturing, and marketing innovative and versatile laser-based medical systems, delivery devices and consumable instrumentation for the ophthalmology market. The Company’s proprietary MicroPulse® technology delivers a differentiated treatment that provides safe, effective, and proven treatment for targeted sight-threatening eye conditions. Iridex’s current product line is used for the treatment of glaucoma, diabetic macular edema (DME) and other retinal diseases. Iridex’s products are sold in the United States through a direct sales force and internationally primarily through a network of independent distributors into more than 100 countries. Iridex is headquartered in Mountain View, CA. Investor Relations Contact: Leigh Salvo 415.937.5404 investors@Iridex.com Media Contact: Jamie Hall Pascale Communications, LLC. 724.417.0167 pr@Iridex.com host Thu, 18 Apr 2019 23:50:00 GMT f1397696-738c-4295-afcd-943feb885714:43 https://iridex.com:443/Default.aspx?tabid=59&articleType=ArticleView&articleId=42#Comments 0 https://iridex.com/DesktopModules/DnnForge%20-%20NewsArticles/RssComments.aspx?TabID=59&ModuleID=524&ArticleID=42 https://iridex.com:443/DesktopModules/DnnForge%20-%20NewsArticles/Tracking/Trackback.aspx?ArticleID=42&PortalID=0&TabID=59 https://iridex.com:443/Default.aspx?tabid=59&articleType=ArticleView&articleId=42 Mountain View, Calif. April 1, 2019 -- Iridex Corporation (NASDAQ: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, announced today that its Cyclo G6® Glaucoma Laser and proprietary MicroPulse® Technology was featured in various posters and presentations at the World Glaucoma Congress last week in Melbourne, Australia. The congress ran from March 27- 31, 2019. Eight world-renowned glaucoma specialists provided hands-on training with the Cyclo G6 Glaucoma Laser to 50 physicians at a wet lab on Friday, March 29th. Additionally, Prof. Paul Chew (Singapore), Dr. Ziad Khoueir (Lebanon), Dr. Shan Lin (United States), Dr. Robert Chang (United States), Dr. Sandra Sieminski (United States), Dr. Victor Koh (Singapore), Dr. Cecilia Aquino (Singapore) and Dr. Ilesh Patel (Australia) provided training, discussed cases, results, technique, and best practices. At the Iridex booth, six MicroPulse laser experts (Dr. Ziad Khouer, Dr. Sandra Sieminski, Dr. Shan Lin, Dr. Robert Chang, Dr. Sheng Lim, and Dr. Vital Paulino Costa) shared experiences, results and best practices with attendees. “There is an increased amount of data surrounding glaucoma treatment with MicroPulse Transscleral Cyclophotocoagulation. Personally, I've had great results treating a wide range of cases with the Cyclo G6 Glaucoma Laser in hundreds of cases, and I am excited to share with a worldwide audience some of my research and patient successes,” said Sheng Lim, MD of St Thomas’ Hospital in United Kingdom. MicroPulse Laser Therapy delivers a differentiated treatment that provides safe, effective, and proven treatment for targeted sight-threatening eye conditions. Over 100,000 patients in more than 50 countries have been treated with the Cyclo G6 Laser, and it is used in the top hospitals in the world, including in 38 of the top 39 hospitals in the United States. The following are some of the symposiums, courses, abstracts and posters where World Glaucoma Congress attendees learned about MicroPulse laser therapy for glaucoma: Lasers in glaucoma: Finding the right spot (Course) Faculty: Ying Han, MD, PhD (United States) MicroPulse and continuous wave CC: early option or last resort (Session) Faculty: Dr. Anton Hommer (Austria) Treatment Outcomes of MP-TSCPC in Refractory Glaucoma Patients in a Tertiary Government Hospital (Abstract) Authors: Raphael Anthony Guballa, Joseph Manuel Cruz Comparison of Outcome Predictors for MicroPulse Laser Trabeculoplasty (Abstract) Authors: Matthew Hirabayashi, Trevor Rosenlof, Jella An Efficacy and Safety of MicroPulse Laser Trabeculoplasty for Primary Open Angle Glaucoma (Abstract) Authors: Ying Hong, Sijia Song, Chun Zhang MP-TSCPC in Controlled Primary Open Angle Glaucoma by Medication (Abstract) Authors: Ivana Liehneova, Soňa Karlovská MP-TSCPC Evaluating the Laser Output of the MP3 Device Following Repeated Use (Abstract) Authors: Katherine Lun, Ekakristiani Suwandono Maya, V. Koh, P.T. Chew A Modified MP-TSCPC Technique for the Treatment of Refractory Glaucoma (Abstract) Authors: Anne Marie Macasaet, Kirsten Wong, Victor Koh, Maria Cecilia D. Aquino, Paul Chew MP-CPC Outcomes in Filipino Patients with Refractory Glaucoma (Abstract) Authors: Aprille June Rapista, Peter Richmond Lee, Ma. Catherina Coronel Nasol The Efficacy and Safety of MP-TSCPC in Japanese Refractory Glaucoma (Abstract) Authors: Risako Yamamoto, Takashi Fujishiro, Koichiro Sugimoto, Shotaro Asano, Kimiko Shimizu, Hiroshi Murata, Rei Sakata, Ryo Asaoka, Megumi Honjo, Makoto Aihara About Iridex Iridex is a worldwide leader in developing, manufacturing, and marketing innovative and versatile laser-based medical systems, delivery devices and consumable instrumentation for the ophthalmology market. The Company’s proprietary MicroPulse® technology delivers a differentiated treatment that provides safe, effective, and proven treatment for targeted sight-threatening eye conditions. Iridex’s current product line is used for the treatment of glaucoma, diabetic macular edema (DME) and other retinal diseases. Iridex’s products are sold in the United States through a direct sales force and internationally primarily through a network of independent distributors into more than 100 countries. Iridex is headquartered in Mountain View, CA. Investor Relations Contact: Leigh Salvo 415.937.5404 investors@Iridex.com Media Contact: Jamie Hall Pascale Communications, LLC. 724.417.0167 pr@Iridex.com host Mon, 01 Apr 2019 19:21:00 GMT f1397696-738c-4295-afcd-943feb885714:42 https://iridex.com:443/Default.aspx?tabid=59&articleType=ArticleView&articleId=41#Comments 0 https://iridex.com/DesktopModules/DnnForge%20-%20NewsArticles/RssComments.aspx?TabID=59&ModuleID=524&ArticleID=41 https://iridex.com:443/DesktopModules/DnnForge%20-%20NewsArticles/Tracking/Trackback.aspx?ArticleID=41&PortalID=0&TabID=59 https://iridex.com:443/Default.aspx?tabid=59&articleType=ArticleView&articleId=41 MOUNTAIN VIEW, Calif., March 5, 2019 -- Iridex Corporation (Nasdaq: IRIX) today reported financial results for the fourth quarter and year ended December 29, 2018. Fourth Quarter Highlights Cyclo G6® Glaucoma Laser product revenue increased by approximately 16% year-over-year Shipped a record 12,300 probes for the Cyclo G6 Laser System Shipped 122 Cyclo G6 Glaucoma Laser Systems Revenue of $11.5 million, a 12% increase year-over-year “I am pleased with the accomplishments of our team in 2018. We took significant steps to grow our market share and future opportunity in glaucoma. The efforts we have made on the commercial front combined with the substantial clinical data supporting our Cyclo G6 Laser System and MicroPulse® technology are increasing the awareness and acceptance of our Cyclo G6 Laser platform, as evidenced by the growth in sales of both Cyclo G6 systems and probes,” said William M. Moore, President and CEO. “In 2019 we look to further leverage our position to grow the installed base, increase probe utilization and introduce new products to enhance our portfolio.” Fourth Quarter 2018 Financial Results Revenue for the three months ended December 29, 2018 increased 12% to $11.5 million from $10.2 million during the same period of the prior year. The increase in revenue was driven by growth from G6 product revenues and complemented by growth in retina product revenues. Gross profit for the fourth quarter of 2018 was $4.7 million, or 41.0% gross margin, compared to $2.2 million, or 21.2% gross margin, in the same period of the prior year. The improvement in gross margin was due primarily to the elimination of costs associated with the voluntary product recall, partially offset by the impact of a shift in product mix. Operating expenses for the fourth quarter of 2018 were $7.6 million compared to $7.4 million in the same period of the prior year. This increase is attributable to investments to support the Company’s commercial infrastructure, including increased sales and marketing, and general and administrative expenses. Loss from operations for the fourth quarter of 2018 was $2.9 million, compared to loss from operations of $5.2 million for the same period of the prior year. Full Year 2018 Financial Results Revenue for the year ended December 29, 2018 increased 2.4% to $42.6 million from $41.6 million in 2017. The increase in revenue was primarily driven by growth from Cyclo G6 product revenues, partially offset by a decrease in retina product revenues. Gross profit for the full year 2018 was $17.5 million, or 41.0% gross margin, compared to $15.5 million, or 37.3% gross margin, for the prior year. The improvement in gross margin was due primarily to lower manufacturing costs and the elimination of costs associated with the voluntary product recall in the prior year period, partially offset by the impact of a shift in geographic mix. Operating expenses for 2018 were $30.3 million compared to $28.4 million in the prior year. This increase is attributable to investments to support the Company’s commercial infrastructure, including increased sales and marketing expenses, and general and administrative expenses. Loss from operations for 2018 was $12.9 million, compared to loss from operations of $12.9 million in the prior year. Cash and cash equivalents were $21.2 million as of December 29, 2018. Guidance for Full Year 2019 Iridex projects shipments of 58,000 to 63,000 probes for the Cyclo G6 system, and projects shipments of 475 to 525 Cyclo G6 systems in 2019. Total revenue for the full year is expected to be $43 million to $46 million. Webcast and Conference Call Information Iridex’s management team will host a conference call today beginning at 2:00 p.m. PT / 5:00 p.m. ET. Investors interested in listening to the conference call may do so by dialing (844) 707-0665 for domestic callers or (703) 326-3030 for international callers, using conference ID: 7159238. A live and archived webcast of the event will be available on the “Investors” section of the Company’s website at: www.Iridex.com. A telephone replay will also be available beginning Tuesday, March 5, 2019 through Wednesday, March 6, 2019, by dialing (855) 859-2056 for domestic callers or (404) 537-3406 for international callers, using conference ID: 7159238. About Iridex Iridex Corporation is a worldwide leader in developing, manufacturing, and marketing innovative and versatile laser-based medical systems, delivery devices and consumable instrumentation for the ophthalmology market. The Company’s proprietary MicroPulse® technology delivers a differentiated treatment that provides safe, effective, and proven treatment for targeted sight-threatening eye conditions. Iridex’s current product line is used for the treatment of glaucoma, diabetic macular edema (DME) and other retinal diseases. Iridex products are sold in the United States through a direct sales force and internationally primarily through a network of independent distributors into more than 100 countries. For further information, visit the Iridex website at http://www.Iridex.com. Safe Harbor Statement This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Act of 1934, as amended, including those statements concerning the future demand, utilization and order levels for the Company's products, plans to introduce new products, and the Company’s guidance for fiscal 2019 and future financial results. These statements are not guarantees of future performance and actual results may differ materially from those described in these forward-looking statements as a result of a number of factors. Please see a detailed description of these and other risks contained in our Annual Report on Form 10-K for the fiscal year ended December 30, 2017, and Quarterly Reports on Form 10-Q for subsequent fiscal quarters, each of which was filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date and will not be updated. Investor Relations Contact: Lynn Pieper Lewis or Leigh Salvo 415.937.5404 investors@Iridex.com host Wed, 06 Mar 2019 05:04:00 GMT f1397696-738c-4295-afcd-943feb885714:41 https://iridex.com:443/Default.aspx?tabid=59&articleType=ArticleView&articleId=40#Comments 0 https://iridex.com/DesktopModules/DnnForge%20-%20NewsArticles/RssComments.aspx?TabID=59&ModuleID=524&ArticleID=40 https://iridex.com:443/DesktopModules/DnnForge%20-%20NewsArticles/Tracking/Trackback.aspx?ArticleID=40&PortalID=0&TabID=59 https://iridex.com:443/Default.aspx?tabid=59&articleType=ArticleView&articleId=40 MOUNTAIN VIEW, Calif., Feb. 26, 2019 -- Iridex Corporation (Nasdaq: IRIX) today announced the Company will release financial results for the fourth quarter and full year 2018 after the close of trading on Tuesday, March 5, 2019. The Company’s management team will host a corresponding conference call beginning at 2:00 p.m. PT / 5:00 p.m. ET. Investors interested in listening to the conference call may do so by dialing (844) 707-0665 for domestic callers or (703) 326-3030 for international callers, using conference ID: 7159238. A live and archived webcast of the event will be available on the “Investors” section of the Company’s website at: www.Iridex.com. A telephone replay will also be available beginning Tuesday, March 5, 2019 through Wednesday, March 6, 2019 by dialing (855) 859-2056 for domestic callers or (404) 537-3406 for international callers, using conference ID: 7159238. For further information, visit the Iridex website at http://www.Iridex.com/. About Iridex Iridex Corporation is a worldwide leader in developing, manufacturing, and marketing innovative and versatile laser-based medical systems, delivery devices and consumable instrumentation for the ophthalmology market. The Company’s proprietary MicroPulse® technology delivers a differentiated treatment that provides safe, effective, and proven treatment for targeted sight-threatening eye conditions. Iridex’s current product line is used for the treatment of glaucoma, diabetic macular edema (DME) and other retinal diseases. Iridex’s products are sold in the United States through a direct sales force and internationally primarily through a network of independent distributors into more than 100 countries. Iridex is headquartered in Mountain View, CA. Investor Relations Contact: Leigh Salvo 415.937.5404 investors@Iridex.com Media Contact: Jamie Hall Pascale Communications, LLC. 724.417.0167 pr@Iridex.com host Tue, 26 Feb 2019 22:50:00 GMT f1397696-738c-4295-afcd-943feb885714:40 https://iridex.com:443/Default.aspx?tabid=59&articleType=ArticleView&articleId=39#Comments 0 https://iridex.com/DesktopModules/DnnForge%20-%20NewsArticles/RssComments.aspx?TabID=59&ModuleID=524&ArticleID=39 https://iridex.com:443/DesktopModules/DnnForge%20-%20NewsArticles/Tracking/Trackback.aspx?ArticleID=39&PortalID=0&TabID=59 https://iridex.com:443/Default.aspx?tabid=59&articleType=ArticleView&articleId=39 MOUNTAIN VIEW, Calif., Feb. 12, 2019 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX) today announced that it has resolved its differences with Quantel Medical, S.A., Quantel USA, Inc., and Quantel, S.A. (collectively, “Quantel”) in its lawsuit filed against Quantel in the U.S. District Court for the Northern District of California. Iridex dismissed the lawsuit it had filed in January 2018, alleging that Quantel products infringed Iridex’s U.S. Patent No. 7,771,417, that Quantel breached an earlier agreement between the parties, and that Quantel infringed Iridex’s MicroPulse® U.S. Trademark, Registration No. 4550188 on the principal register. Quantel dismissed its lawsuit in Europe including Tribunal de grande instance de Paris, 3e chamber, 1e section, RG n° 18/06053, related to European patent n° 1 856 774 against Iridex and withdrew from participation in the Opposition to Iridex’s European Patent No. 1856774. Iridex filed a Notice of Appeal with the European Patent Office (EPO) in that proceeding in October 2018. "We place a high priority defending our intellectual property and I am very pleased with the swift resolution of the U.S. lawsuit and the intellectual property claims in Europe. Our MicroPulse technology and its brand recognition now remain protected from competitive misuse and misrepresentation," stated William Moore, President, and CEO. “We are now able to confidently move forward in devoting our resources to further developing and marketing our proprietary laser technology for treating sight-threatening eye diseases, such as glaucoma and retinal diseases.” Iridex’s MicroPulse technology delivers a tissue-sparing solution that allows the tissue to cool between laser pulses, minimizing or preventing tissue damage, reducing treatment risks, and improving patient comfort and safety. About Iridex Iridex Corporation is a worldwide leader in developing, manufacturing, and marketing innovative and versatile laser-based medical systems, delivery devices and consumable instrumentation for the ophthalmology market. The Company’s proprietary MicroPulse® technology delivers a differentiated treatment that provides safe, effective, and proven treatment for targeted sight-threatening eye conditions. Iridex’s current product line is used for the treatment of glaucoma, diabetic macular edema (DME) and other retinal diseases. Iridex’s products are sold in the United States through a direct sales force and internationally primarily through a network of independent distributors into more than 100 countries. Iridex is headquartered in Mountain View, CA. Investor Relations Contact: Lynn Pieper Lewis or Leigh Salvo 415.937.5404 investors@Iridex.com Media Contact: Jamie Hall Pascale Communications, LLC. 724.417.0167 pr@Iridex.com host Tue, 12 Feb 2019 21:33:00 GMT f1397696-738c-4295-afcd-943feb885714:39 https://iridex.com:443/Default.aspx?tabid=59&articleType=ArticleView&articleId=38#Comments 0 https://iridex.com/DesktopModules/DnnForge%20-%20NewsArticles/RssComments.aspx?TabID=59&ModuleID=524&ArticleID=38 https://iridex.com:443/DesktopModules/DnnForge%20-%20NewsArticles/Tracking/Trackback.aspx?ArticleID=38&PortalID=0&TabID=59 https://iridex.com:443/Default.aspx?tabid=59&articleType=ArticleView&articleId=38 Mountain View, Calif., January 8, 2019 — Iridex Corporation (Nasdaq: IRIX) today provided preliminary operational and financial results for the fourth quarter and full year ended December 29, 2018. Highlights Shipped approximately 460 to 465 Cyclo G6® Glaucoma Laser Systems and 45,500 to 46,500 G6 probes in the full year 2018 Shipped approximately 119 to 124 Cyclo G6® Glaucoma Laser Systems and a record 12,000 to 13,000 G6 probes in the fourth quarter 2018 Total revenue for 2018 expected to be $42.1 million to $42.4 million, representing an increase of 1.3% to 2.0% over 2017 Total revenue for the fourth quarter of 2018 expected to be $11.0 million to $11.3 million, representing an increase of 7.4% to 10.3% over the fourth quarter of 2017 “Our fourth quarter results completed an exciting year for Iridex. Our commercial teams continued to drive growth in Cyclo G6 placements and we shipped a record number of G6 probes in the quarter. Overall, I am encouraged by the progress we made throughout the year, as we executed on multiple fronts across the organization," said William M. Moore, Chairman and Chief Executive Officer. "Heading into 2019, we remain focused on driving awareness and sales among a broad base of glaucoma specialists and comprehensive ophthalmologists, while continuing to innovate and advance our platform to treat the spectrum of the disease." These preliminary results are based on management's initial analysis of operations for the quarter and year ended December 29, 2018 and are subject to further internal review and audit by the Company's external auditors. Iridex expects to issue full 2018 financial results in early March 2019, at which time the Company plans to provide guidance for full year 2019. About Iridex Iridex Corporation is a worldwide leader in developing, manufacturing, and marketing innovative and versatile laser-based medical systems, delivery devices and consumable instrumentation for the ophthalmology market. The Company’s proprietary MicroPulse® technology delivers a differentiated treatment that provides safe, effective, and proven treatment for targeted sight-threatening eye conditions. Iridex’s current product line is used for the treatment of glaucoma, diabetic macular edema (DME) and other retinal diseases. Iridex’s products are sold in the United States through a direct sales force and internationally primarily through a network of independent distributors into more than 100 countries. Iridex is headquartered in Mountain View, CA. Safe Harbor Statement This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Act of 1934, as amended, including those statements concerning the Company’s preliminary, unaudited Cyclo G6 system and probe shipments and revenues for the fourth quarter and full year 2018, and the timing of the release of the Company’s complete financial results for the fourth quarter and full year 2018 and guidance for full year 2019. These statements are not guarantees of future performance and actual results may differ materially from those described in these forward-looking statements as a result of a number of factors. Please see a detailed description of these and other risks contained in our Annual Report on Form 10-K for the fiscal year ended December 30, 2017, and Quarterly Reports on Form 10-Q for subsequent fiscal quarters, each of which was filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date and will not be updated. Investor Relations Contact: Leigh Salvo 415.937.5404 investors@Iridex.com Media Contact: Jamie Hall Pascale Communications, LLC. 724.417.0167 jamie@pascalecommunications.com host Wed, 09 Jan 2019 00:15:00 GMT f1397696-738c-4295-afcd-943feb885714:38 https://iridex.com:443/Default.aspx?tabid=59&articleType=ArticleView&articleId=37#Comments 0 https://iridex.com/DesktopModules/DnnForge%20-%20NewsArticles/RssComments.aspx?TabID=59&ModuleID=524&ArticleID=37 https://iridex.com:443/DesktopModules/DnnForge%20-%20NewsArticles/Tracking/Trackback.aspx?ArticleID=37&PortalID=0&TabID=59 https://iridex.com:443/Default.aspx?tabid=59&articleType=ArticleView&articleId=37 Mountain View, Calif., December 4, 2018— Iridex Corporation (Nasdaq: IRIX) today announced Chief Financial Officer Atabak Mokari will leave the Company for a senior finance executive role at another company. Mokari has agreed to assist in the orderly transition of his CFO responsibilities and will leave the Company effective December 18, 2018. Iridex plans to search for a replacement. “We would like to thank Atabak for his service throughout the significant transformation of our business into the glaucoma treatment market,” said William M. Moore, Chairman and Chief Executive Officer. “With a high level of professionalism and dedication, he led us through multiple capital raises and assisted in the transition of our organization. We wish him well in his next endeavor. “As we identify a replacement, Romeo Dizon, Vice President of Finance will be assuming responsibility for financial controls and reporting. During his lengthy tenure with the Company, he has previously stepped successfully into this role before and we are very confident in his abilities,” Moore concluded. "The motivated and talented team at Iridex has been a pleasure to work with," said Atabak Mokari, Chief Financial Officer. "I am proud of our accomplishments over the last few years. The opportunity in glaucoma continues to grow and I am confident the Company is well positioned to further penetrate and make inroads throughout the glaucoma treatment continuum." Guidance for Full Year 2018 Iridex reiterates its guidance range for G6 systems, probes and total revenue. The Company expects G6 system shipments of 430 to 450, G6 probe shipments of 44,000 to 46,000 and total revenue of $41 million to $42 million. About Iridex Iridex Corporation is a worldwide leader in developing, manufacturing, and marketing innovative and versatile laser-based medical systems, delivery devices and consumable instrumentation for the ophthalmology market. The Company’s proprietary MicroPulse® technology delivers a differentiated treatment that provides safe, effective, and proven treatment for targeted sight-threatening eye conditions. Iridex’s current product line is used for the treatment of glaucoma, diabetic macular edema (DME) and other retinal diseases. Iridex’s products are sold in the United States through a direct sales force and internationally primarily through a network of independent distributors into more than 100 countries. Iridex is headquartered in Mountain View, CA. Investor Relations Contact: Lynn Pieper Lewis or Leigh Salvo 415.937.5404 investors@Iridex.com Media Contact: Jamie Hall Pascale Communications, LLC. 724.417.0167 pr@Iridex.com host Tue, 04 Dec 2018 17:10:00 GMT f1397696-738c-4295-afcd-943feb885714:37 https://iridex.com:443/Default.aspx?tabid=59&articleType=ArticleView&articleId=36#Comments 0 https://iridex.com/DesktopModules/DnnForge%20-%20NewsArticles/RssComments.aspx?TabID=59&ModuleID=524&ArticleID=36 https://iridex.com:443/DesktopModules/DnnForge%20-%20NewsArticles/Tracking/Trackback.aspx?ArticleID=36&PortalID=0&TabID=59 https://iridex.com:443/Default.aspx?tabid=59&articleType=ArticleView&articleId=36 Mountain View, Calif., October 25, 2018 — Iridex Corporation (Nasdaq: IRIX) today announced the Company plans to participate in upcoming investor conferences. Iridex’s management is scheduled to present at the Stephens NY Investment Conference on Wednesday, November 7th, 2018 at 4:00 pm Eastern Time. Iridex’s management is scheduled to present at the Stifel Healthcare Conference in New York City on Tuesday, November 13th, 2018 at 3:30 pm Eastern Time. Interested parties may access a live and archived webcast of both presentations from the Investor Events section of the Company’s website at www.Iridex.com. About Iridex Iridex Corporation is a worldwide leader in developing, manufacturing, and marketing innovative and versatile laser-based medical systems, delivery devices and consumable instrumentation for the ophthalmology market. The Company’s proprietary MicroPulse® technology delivers a differentiated treatment that provides safe, effective, and proven treatment for targeted sight-threatening eye conditions. Iridex’s current product line is used for the treatment of glaucoma, diabetic macular edema (DME) and other retinal diseases. Iridex’s products are sold in the United States through a direct sales force and internationally primarily through a network of independent distributors into more than 100 countries. Iridex is headquartered in Mountain View, CA. Investor Relations Contact: Lynn Pieper Lewis or Leigh Salvo 415.937.5404 investors@Iridex.com Media Contact: Jamie Hall Pascale Communications, LLC. 724.417.0167 pr@Iridex.com host Thu, 25 Oct 2018 22:01:00 GMT f1397696-738c-4295-afcd-943feb885714:36 https://iridex.com:443/Default.aspx?tabid=59&articleType=ArticleView&articleId=35#Comments 0 https://iridex.com/DesktopModules/DnnForge%20-%20NewsArticles/RssComments.aspx?TabID=59&ModuleID=524&ArticleID=35 https://iridex.com:443/DesktopModules/DnnForge%20-%20NewsArticles/Tracking/Trackback.aspx?ArticleID=35&PortalID=0&TabID=59 https://iridex.com:443/Default.aspx?tabid=59&articleType=ArticleView&articleId=35 Glaucoma and Retina Specialists Will Discuss the Benefits of MicroPulse® Technology MOUNTAIN VIEW, Calif., Oct. 23, 2018 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq:IRIX), a leading provider of innovative laser systems in ophthalmology, will be hosting a series of panel discussions at the American Academy of Ophthalmology (AAO) in Chicago, IL on October 27-29, 2018. Twenty-seven leading glaucoma and retina specialists from around the world will highlight how they are using Iridex lasers in MicroPulse® mode to treat early to late stage glaucoma and several retina diseases. “Laser treatment for glaucoma has evolved significantly, allowing ophthalmologists to treat a wider variety of patients. Treatment of glaucoma with Iridex’s MicroPulse P3 device extends well beyond refractory stage applications. In patients with moderate to severe disease, I have had great success with open angle and angle closure glaucoma. Moreover, the versatility of the procedure with the MicroPulse P3 gives us the opportunity to extend this treatment to patients with good central vision and those with earlier stage glaucoma. At the upcoming AAO meeting, I plan to share clinical data during a poster session and during Iridex’s Forum Panel Presentations,” states Sandra Fernando-Sieminski, MD, Director of Glaucoma Service at University at Buffalo in New York. Lawrence Morse, MD, PhD, Professor of Ophthalmology and Director of Retina Services at the University of California Davis, shared, “MicroPulse Laser Therapy is an effective and gentle procedure for the treatment of diabetic macular edema (DME) and other retinal diseases. My research and clinical experience confirm that the combination of MicroPulse and anti-VEGF therapy may help to reduce the treatment burden on patients with DME. I am looking forward to discussing the many benefits of MicroPulse with colleagues at one of Iridex’s Forum Panel Presentations.” The roundtable discussions will take place on Saturday, October 27 through Monday, October 29th. The program is as follows: Saturday, October 27 10:30-11:30 AM: Glaucoma Panel - MicroPulse: Myth or Messiah? Oluwatosin Smith, MD; Michael Giovingo, MD; Rohit Krishna, MD; David Gossage, DO 1:30-2:30 PM: Retina Panel - MicroPulse laser therapy for CSCR and DME retinal disorders Larry Morse, MD, PhD; Glenn Yiu, MD, PhD; Caesar Luo, MD, FACS; Roger Goldberg, MD, MBA 3:00-4:00 PM: Glaucoma Presentation - MicroPulse Cyclophotocoagulation: A look at long term efficacy and outcomes Nathan Radcliffe, MD Sunday, October 28 9:00-9:30 AM: Retina Presentation - The mechanism of HSP expression post MicroPulse therapy for retinal disorders Kishiko Ohkoshi, MD, PhD (Japan) 10:30-11:30 AM: Glaucoma Panel - MicroPulse TSCPC: It is not just for end stage glaucoma Robert Noecker, MD, MBA; Sandra Fernando Sieminski, MD; Syril K. Dorairaj, MD, FACS; Bret Crumpton, DO 1:30-2:30 PM: Retina Panel - When injections are not enough: learn about your therapeutic choices with MicroPulse therapy Marco Zarbin, MD, PhD; Ted Leng, MD, FACS; Julia Schulman, MD; Dana Dupree, MD; Jeevan Mathura, MD 3:00-4:00 PM: Comprehensive Presentation - 2- and 3-year outcomes for mild glaucoma with the Cyclo G6® laser Ahad Mahootchi, MD Monday, October 29 10:30-11:30 AM: Glaucoma Panel - Experiences with MicroPulse P3™ procedure in the US and abroad: A non-incisional approach to glaucoma treatment Jeffrey Kammer, MD; Arthur Resende, MD; Vital Paulino Costa, MD; Shamil Patel, MD 1:30-2:30 PM: Retina Panel: MicroPulse and CSCR: A game changer Munir Escaf, MD (Colombia); Sergio Rojas, MD (Mexico); Karen Barraza, MD (Peru) In addition to the panels, Iridex’s glaucoma treatment will be featured at AAO’s Skills Transfer Lab on Sunday, and Iridex will be offering hands-on demos in the booth, #3721. To learn more about joining these events please visit Iridex.com/aao. Data of Note Iridex technologies will also be represented through scientific data presentations. Two data sets will review positive results from a total of 68 eyes treating with MicroPulse. PO096 - Success Rate and Safety of MicroPulse Trans-scleral CPC With Variable Treatment Durations in Glaucoma Sunday, October 28th; 12:45 PM Author: Dr Robert Noecker PO384 - Safety and Efficacy of MicroPulse Trans-scleral CPC in Eyes with Good Central Vision Monday, October 29th; 12:45 PM Author: Sandra Sieminski, MD The AAO meeting anticipates welcoming over 20,000+ ophthalmologists, health professionals and industry personnel from around the world will convene in Chicago to hear from thought leaders, gain insights into practice management trends and get hands-on experience with cutting-edge treatment techniques. About Iridex Iridex is a worldwide leader in developing innovative and versatile laser-based medical systems, delivery devices and consumable instrumentation for the ophthalmology market. The Company’s proprietary MicroPulse® technology delivers a differentiated treatment that provides safe, effective, and proven treatment for targeted sight-threatening eye conditions. Iridex’s current product line is used for the treatment of glaucoma, diabetic macular edema (DME) and other retinal diseases.  Iridex products are sold in the United States and Germany through a direct sales force and in more than 100 countries through a network of independent distributors. For more information, visit www.Iridex.com. Media Contact: Jamie Hall Pascale Communications, LLC. 724.417.0167 pr@Iridex.com Investor Relations Lynn Pieper Lewis or Leigh Salvo 415.937.5404 investors@Iridex.com host Tue, 23 Oct 2018 21:48:00 GMT f1397696-738c-4295-afcd-943feb885714:35 https://iridex.com:443/Default.aspx?tabid=59&articleType=ArticleView&articleId=33#Comments 0 https://iridex.com/DesktopModules/DnnForge%20-%20NewsArticles/RssComments.aspx?TabID=59&ModuleID=524&ArticleID=33 https://iridex.com:443/DesktopModules/DnnForge%20-%20NewsArticles/Tracking/Trackback.aspx?ArticleID=33&PortalID=0&TabID=59 https://iridex.com:443/Default.aspx?tabid=59&articleType=ArticleView&articleId=33 World-Renowned Ophthalmologists to Highlight Benefits of MicroPulse® Technology in Treating Patients with Glaucoma and Retinal Diseases MOUNTAIN VIEW, Calif., September 18, 2018 -- Iridex Corporation (Nasdaq:IRIX), a leading provider of innovative laser systems in ophthalmology, today announced they will be hosting a symposium at the Annual Meeting of the European Society for Cataract and Refractive Surgeons (ESCRS) in Vienna, Austria on September 22, 2018. MicroPulse® Technology: Latest Trends in Laser Treatment Choices for Glaucoma and Retinal Diseases will feature five world-renowned glaucoma and retina specialists who plan to share how they are using the Company’s MicroPulse technology. The one-hour session will feature multiple cases, results, and include time for audience questions. Sandra Fernando Sieminski, MD, the Director of Glaucoma Service at the University of Buffalo in New York, USA, will be one of five presenters at the symposium. “Laser treatment for glaucoma has evolved significantly and many ophthalmologists do not recognize the wide variety of patients that may greatly benefit from treatment with Iridex’s MicroPulse P3 device. For example, in patients with moderate to severe disease, I have had great success with open angle, angle closure, and pseudoexfoliative glaucoma. At the symposium, my colleagues and I expect to share our data that highlights many of these new benefits,” states Dr. Sieminksi. Matteo Forlini, MD, a vitreoretinal surgeon at Domus Nova Hospital in Ravenna, Italy, will also share his experiences at the symposium. “We continue to increase our understanding of the benefits of MicroPulse Laser Therapy in conjunction with anti-VEGF for the treatment of macular edema. I look forward to sharing my results in Vienna,” states Dr. Forlini. The symposium will take place on Saturday, September 22 from 13:00-14:00 in room Lehar 2. The program is as follows: 13:00 – 13:02 - Marc Toeteberg (University Hospital Zurich, Switzerland) Introduction 13:02 – 13:12 - Matteo Forlini, MD (Domus Nova Hospital, Ravenna, Italy) Successful MicroPulse Treatment for Macular Edema in Retinal Vein Occlusion 13:12 – 13:22 - Boris Stanzel, MD, FEBO (Knappschaft Eye Hospital, Sulzbach, Germany) MicroPulse Laser Induced Macular Remodeling After ILM Peeling in Full Thickness Macular Holes 13:22 – 13:32 - Sandra Sieminski, MD (University at Buffalo, Buffalo, NY, USA) MicroPulse P3 Procedure for Various Glaucoma Patients: Going Beyond Late Stage Disease 13:32 – 13:42 - Marc Toeteberg, MD, FEBO (University Hospital Zurich, Switzerland) MicroPulse CPC Glaucoma Treatment and Patient’s Profiles: University of Zurich Experience 13:42 – 13:52 - K. Sheng Lim, MBChB, MD, FRCOphth (St Thomas' Hospital, United Kingdom) Updates from the MicroPulse Aqueous Dynamics Study in Early or moderate POAG 13:52 - 14:00 - Questions and Answers In addition to the symposium, Iridex will be offering a “Speak with MicroPulse Experts” event at its booth (C501) every day between 10:30-11:30 and 14:00-15:00. Physicians will have the opportunity to speak with glaucoma or retina specialists about their experiences treating a wide variety of cases using Iridex lasers in MicroPulse mode. Glaucoma is the second most common cause of blindness in the world, and surgical interventions are not always possible for certain patients. MicroPulse Cyclophotocoagulation (CPC) is a safe and effective treatment option for a variety of types of glaucoma, and it can be performed either in the operating room or as an outpatient, office-based procedure. The ESCRS Congress anticipates welcoming over 7,500 ophthalmologists from 130 countries in Vienna, Austria. The meeting takes place from September 22-26 at the Messe Wien Exhibition and Congress Center. Registration for the MicroPulse symposium can be completed at www.Iridex.com/escrs. About Iridex Iridex is a worldwide leader in developing innovative and versatile laser-based medical systems, delivery devices and consumable instrumentation for the ophthalmology market. The Company’s proprietary MicroPulse® technology delivers a differentiated treatment that provides safe, effective, and proven treatment for targeted sight-threatening eye conditions. Iridex’s current product line is used for the treatment of glaucoma, diabetic macular edema (DME) and other retinal diseases.  Iridex products are sold in the United States and Germany through a direct sales force and in more than 100 countries through a network of independent distributors. For more information, visit www.Iridex.com. Media Contact: Jamie Hall Pascale Communications, LLC. 724.417.0167 pr@Iridex.com Investor Relations Lynn Pieper Lewis or Leigh Salvo 415.937.5404 investors@Iridex.com host Tue, 18 Sep 2018 16:29:00 GMT f1397696-738c-4295-afcd-943feb885714:33 https://iridex.com:443/Default.aspx?tabid=59&articleType=ArticleView&articleId=32#Comments 0 https://iridex.com/DesktopModules/DnnForge%20-%20NewsArticles/RssComments.aspx?TabID=59&ModuleID=524&ArticleID=32 https://iridex.com:443/DesktopModules/DnnForge%20-%20NewsArticles/Tracking/Trackback.aspx?ArticleID=32&PortalID=0&TabID=59 https://iridex.com:443/Default.aspx?tabid=59&articleType=ArticleView&articleId=32 Mountain View, Calif., September 6, 2018— Iridex Corporation (Nasdaq: IRIX) today announced the introduction of its updated TruFocus LIO Premiere™ laser accessory following U.S. Food and Drug Administration (FDA) 510(k) review and clearance. The TruFocus LIO Premiere is a light combination and reflection viewing system used with Iridex retina laser systems and is worn on the physician’s head. The product combines a laser treatment beam from an Iridex laser source with the illumination beam of a binocular indirect ophthalmoscope into a mixed optical beam used by a physician with a handheld ophthalmic examination lens to enter a patient’s pupil and to view and treat a patient’s retina. It provides a portable alternative to patients who cannot be examined or treated with a fixed slit lamp adapter. The device can be used to evaluate and treat patients of all ages, including infants, in an office, operating room and ambulatory surgical center setting. “We are pleased to again be offering our full portfolio of laser delivery devices to doctors in the U.S.,” said William M. Moore, President and Chief Executive Officer. “We would like to thank our team and the FDA for their diligent attention to this matter.” About Iridex Iridex Corporation is a worldwide leader in developing, manufacturing, and marketing innovative and versatile laser-based medical systems, delivery devices and consumable instrumentation for the ophthalmology market. The Company’s proprietary MicroPulse® technology delivers a differentiated treatment that provides safe, effective, and proven treatment for targeted sight-threatening eye conditions. Iridex’s current product line is used for the treatment of glaucoma, diabetic macular edema (DME) and other retinal diseases. Iridex products are sold in the United States through a direct sales force and internationally primarily through a network of independent distributors into more than 100 countries. For further information, visit www.Iridex.com. Safe Harbor Statement This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Act of 1934, as amended, including those statements concerning future sales of Company products and industry trends. These statements are not guarantees of future performance and actual results may differ materially from those described in these forward-looking statements as a result of a number of factors, including the Company’s ability to execute on its strategic goals, market adoption of its products and industry developments. Please see a detailed description of these and other risks contained in our Annual Report on Form 10-K for the fiscal year ended December 30, 2017, and Quarterly Reports on Form 10-Q for subsequent fiscal quarters, each of which was filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date and will not be updated. Media Contact: Jamie Hall Pascale Communications, LLC. 724.417.0167 pr@Iridex.com Investor Relations Lynn Pieper Lewis or Leigh Salvo 415.937.5404 investors@Iridex.com host Thu, 06 Sep 2018 22:02:00 GMT f1397696-738c-4295-afcd-943feb885714:32 https://iridex.com:443/Default.aspx?tabid=59&articleType=ArticleView&articleId=31#Comments 0 https://iridex.com/DesktopModules/DnnForge%20-%20NewsArticles/RssComments.aspx?TabID=59&ModuleID=524&ArticleID=31 https://iridex.com:443/DesktopModules/DnnForge%20-%20NewsArticles/Tracking/Trackback.aspx?ArticleID=31&PortalID=0&TabID=59 https://iridex.com:443/Default.aspx?tabid=59&articleType=ArticleView&articleId=31 Recent Study Published by U.S. News and World Report Highlighting the “Best Hospitals for Ophthalmology” Includes 35 Iridex Customers Mountain View Calif., August 30, 2018 -- Iridex Corporation (Nasdaq: IRIX), a leading provider of innovative laser systems in ophthalmology, is pleased to announce that the Company’s Cyclo G6 Glaucoma Laser System is used in 35 of the 39 “Best Hospitals for Ophthalmology” as ranked in a recent report by U.S. News and World Report. The Cyclo G6 system is the first in its class designed specifically to treat patients diagnosed with a range of glaucoma disease states. It features the Company’s proprietary MicroPulse technology, in which a continuous-wave laser beam is chopped into a train of tiny, repetitive, low energy pulses separated by a brief rest period allowing the tissue to cool between laser pulses. U.S. News and World Report’s “Best Hospitals: Specialty Rankings” is provided annually with a focus on identifying hospitals that excel in treating particularly difficult patients. In the 2017-2018 rankings, over 4,500 U.S. hospitals were evaluated. Specialty hospitals must meet a volume/discharge threshold and be recommended by a minimum number of specialists. “I have been using the MicroPulse Transscleral Cyclophotocoagulation (MP-TSCPC) procedure with the Cyclo G6 laser and the MicroPulse P3 probe for more than two years. MicroPulse mode has proven to be an efficacious choice for many of my glaucoma patients, providing significant reduction in pressure and medication use. I have found that after MP-TSCPC procedures, my patients experience less pain and post-procedural inflammation than after traditional Cyclophotocoagulation (CPC),” said Dr. Jonathan S. Myers, Chief Glaucoma Service at Wills Eye Hospital. Since its launch in 2015, approximately 1,100 G6 systems and approximately 90,000 G6 probes have been shipped to over 50 countries. “A key component of our strategy in the U.S. is building and expanding relationships with the largest and best ophthalmology hospitals in the country. We are delighted to see most of the facilities named in this report already on the Iridex customer list. We believe this both validates our technology and demonstrates the opportunity we have to expand utilization within a wide range of notable institutions,” said William Moore, Chief Executive Officer of Iridex. About Iridex Iridex Corporation is a worldwide leader in developing, manufacturing, and marketing innovative and versatile laser-based medical systems, delivery devices and consumable instrumentation for the ophthalmology market. The Company’s proprietary MicroPulse® technology delivers a differentiated treatment that provides safe, effective, and proven treatment for targeted sight-threatening eye conditions. Iridex’s current product line is used for the treatment of glaucoma, diabetic macular edema (DME) and other retinal diseases. Iridex products are sold in the United States through a direct sales force and internationally primarily through a network of independent distributors into more than 100 countries. For further information, visit www.Iridex.com. Safe Harbor Statement This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Act of 1934, as amended, including those statements concerning future sales of Company products and industry trends. These statements are not guarantees of future performance and actual results may differ materially from those described in these forward-looking statements as a result of a number of factors, including the Company’s ability to execute on its strategic goals, market adoption of its products and industry developments. Please see a detailed description of these and other risks contained in our Annual Report on Form 10-K for the fiscal year ended December 30, 2017, and Quarterly Reports on Form 10-Q for subsequent fiscal quarters, each of which was filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date and will not be updated. Media Contact: Jamie Hall Pascale Communications, LLC. 724.417.0167 pr@Iridex.com Investor Relations Lynn Pieper Lewis or Leigh Salvo 415.937.5404 investors@Iridex.com host Thu, 30 Aug 2018 17:37:00 GMT f1397696-738c-4295-afcd-943feb885714:31 https://iridex.com:443/Default.aspx?tabid=59&articleType=ArticleView&articleId=30#Comments 0 https://iridex.com/DesktopModules/DnnForge%20-%20NewsArticles/RssComments.aspx?TabID=59&ModuleID=524&ArticleID=30 https://iridex.com:443/DesktopModules/DnnForge%20-%20NewsArticles/Tracking/Trackback.aspx?ArticleID=30&PortalID=0&TabID=59 https://iridex.com:443/Default.aspx?tabid=59&articleType=ArticleView&articleId=30 Mountain View Calif., July 20, 2018 — The award-winning series, Innovations with Ed Begley Jr., will feature Iridex Corporation (Nasdaq: IRIX) technology in an upcoming episode scheduled to air on CNBC on Sunday, July 22, 2018 at 3:30 ET. In this episode, the show will explore Iridex’s patented MicroPulse® Laser Technology; a tissue-sparing solution for the treatment of retinal diseases and glaucoma, and Iridex’s latest laser, the CYCLO G6™ Glaucoma Laser. MicroPulse technology splits a continuous-wave laser beam into short, repetitive, low energy pulses separated by a brief rest period. The shorter exposure time allows the tissue to cool between laser pulses, helping to minimize and prevent tissue damage during ophthalmic coagulation procedures. Innovations, hosted by award winning actor Ed Begley, Jr., is an information-based series geared toward educating the public on the latest breakthroughs in all areas of society. Featuring practical solutions and important issues facing consumers and professionals alike, Innovations focuses on cutting-edge advancements in everything from health and wellness to global business, renewable energy, and more. host Fri, 20 Jul 2018 17:33:00 GMT f1397696-738c-4295-afcd-943feb885714:30 https://iridex.com:443/Default.aspx?tabid=59&articleType=ArticleView&articleId=29#Comments 0 https://iridex.com/DesktopModules/DnnForge%20-%20NewsArticles/RssComments.aspx?TabID=59&ModuleID=524&ArticleID=29 https://iridex.com:443/DesktopModules/DnnForge%20-%20NewsArticles/Tracking/Trackback.aspx?ArticleID=29&PortalID=0&TabID=59 https://iridex.com:443/Default.aspx?tabid=59&articleType=ArticleView&articleId=29 Important Commercial Milestone Demonstrates Growing Worldwide Awareness of MicroPulse Technology for Treatment of Glaucoma Mountain View Calif., July 10, 2018 -- Iridex Corporation (Nasdaq: IRIX) today announced that in the second quarter of 2018 it has shipped the 1,000th unit of its Cyclo G6™ Laser System, which utilizes the Company’s proprietary MicroPulse® technology for the treatment of glaucoma. Dr. Ryo Taniguchi, of the Taniguchi Eye Clinic in Japan, Kyoshu Saga Prefecture, was the recipient of the 1,000th system. “MicroPulse Laser therapy is a new and very promising technology in Japan, providing an effective and non-incisional treatment for glaucoma patients with a range of stages of the disease. The earlier clinical research performed in US, Europe and Asia showed that MicroPulse is safe and effective in IOP reduction and medication use decrease, and my clinical findings confirm the previous studies’ results. As one of the first sites in Japan to use the Cyclo G6 for glaucoma treatment, we have seen significant benefits. Even patients with previous intraocular surgeries experienced positive results,” said Makoto Aihara MD, PhD, Professor and Chair, University of Tokyo. The Cyclo G6 system is supported by a growing body of clinical evidence and extensive validation in the field for the treatment of glaucoma. Physicians worldwide have adopted the Cyclo G6 because it is safe, minimally invasive, non-incisional, repeatable and durable. Moreover, the Cyclo G6 provides physicians and the healthcare system a cost-effective solution for the treatment of glaucoma across the full continuum of care – from early to late stage glaucoma. More than 80,000 patients worldwide have been treated with the Cyclo G6 system. “In my opinion, MicroPulse Laser therapy shifts the paradigm of glaucoma treatments in Japan. It provides a new choice for a safe, effective, and non-incisional treatment on various glaucoma patients with mild, moderate, and late stage disease. The MicroPulse procedure can be performed on a wide variety of patients not responding to medications or not qualified for incisional surgeries. Recent industry meetings and clinical presentations of leading physicians using the MicroPulse procedure in the United States, Europe and Asia have demonstrated and proven that fact. My initial clinical experience with it confirms these findings,” commented Dr. Ryo Taniguchi. “We are delighted to achieve this exciting milestone in the commercialization of our Cyclo G6 laser system, as it not only demonstrates the traction the platform is gaining worldwide, but highlights the progress we have made in transforming our business to delivering a compelling and proven treatment alternative for patients suffering from glaucoma,” said William Moore, Chief Executive Officer of Iridex. About Iridex Iridex is a worldwide leader in developing innovative and versatile laser-based medical systems, delivery devices and consumable instrumentation for the ophthalmology market. The Company’s proprietary MicroPulse technology delivers a differentiated treatment that provides safe, effective, and proven treatment for targeted sight-threatening eye conditions. Iridex’s current product line is used for the treatment of glaucoma, diabetic macular edema (DME) and other retinal diseases. Iridex products are sold in the United States and Germany through a direct sales force and in more than 100 countries through a network of independent distributors. For more information, visit Iridex.com. Safe Harbor Statement This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Act of 1934, as amended, including those statements concerning future sales of Company products and industry trends. These statements are not guarantees of future performance and actual results may differ materially from those described in these forward-looking statements as a result of a number of factors, including the Company’s ability to execute on its strategic goals, market adoption of its products and industry developments. Please see a detailed description of these and other risks contained in our Annual Report on Form 10-K for the fiscal year ended December 30, 2017, and Quarterly Reports on Form 10-Q for subsequent fiscal quarters, each of which was filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date and will not be updated. Media Contact: Jamie Hall Pascale Communications, LLC. 724.417.0167 jamie@pascalecommunications.com Investor Relations Contact Lynn Pieper Lewis or Leigh Salvo 415.937.5404 investors@Iridex.com host Tue, 10 Jul 2018 20:37:00 GMT f1397696-738c-4295-afcd-943feb885714:29 https://iridex.com:443/Default.aspx?tabid=59&articleType=ArticleView&articleId=28#Comments 0 https://iridex.com/DesktopModules/DnnForge%20-%20NewsArticles/RssComments.aspx?TabID=59&ModuleID=524&ArticleID=28 https://iridex.com:443/DesktopModules/DnnForge%20-%20NewsArticles/Tracking/Trackback.aspx?ArticleID=28&PortalID=0&TabID=59 https://iridex.com:443/Default.aspx?tabid=59&articleType=ArticleView&articleId=28 MOUNTAIN VIEW, Calif., June 19, 2018 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq:IRIX) today announced the approval of its CYCLO G6™ Glaucoma Laser system by South Korea's Ministry of Food and Drug Safety (MFDS). Currently available in more than 50 countries, the CYCLO G6 treats patients diagnosed with a range of glaucoma disease states using the Company’s proprietary MicroPulse® technology and a family of single use probes. “International expansion in the Asia-Pacific region remains a top priority for us and we believe that Korea represents an attractive market opportunity for our G6 technology,” said William M. Moore, President and Chief Executive Officer. “We set G6 approval in Korea as a key target for our 2018 expansion strategy and I am delighted to have reached this key milestone. Importantly, we have already started to garner feedback and support from key opinion leaders in the region and expect to leverage their support in our launch strategy.” The CYCLO G6 platform is supported by a growing body of clinical evidence and extensive validation in the field for the treatment of glaucoma. Physicians worldwide have adopted the G6 because it is safe, minimally invasive, non-incisional, repeatable and durable. Moreover, the G6 provides physicians and the healthcare system a cost-effective solution for the treatment of glaucoma across the full continuum of care – from early stage to late stage glaucoma. "We believe these tangible reasons are driving increased awareness and excitement in the worldwide glaucoma community for our G6. We look forward to continued success accelerating CYCLO G6 adoption and utilization,” concluded Moore. About Iridex Iridex Corporation is a worldwide leader in developing, manufacturing, and marketing innovative and versatile laser-based medical systems, delivery devices and consumable instrumentation for the ophthalmology market. The Company’s proprietary MicroPulse® technology delivers a differentiated treatment that provides safe, effective, and proven treatment for targeted sight-threatening eye conditions. Iridex’s current product line is used for the treatment of glaucoma, diabetic macular edema (DME) and other retinal diseases. Iridex products are sold in the United States through a direct sales force and internationally primarily through a network of independent distributors into more than 100 countries. For further information, visit the Iridex website at http://www.Iridex.com/ Safe Harbor Statement This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Act of 1934, as amended, including those statements concerning the Company’s strategic priorities, market opportunity in Korea, marketing and launch strategy, and plans to accelerate CYCLO G6 adoption and utilization. These statements are not guarantees of future performance and actual results may differ materially from those described in these forward-looking statements as a result of a number of factors, including the Company’s ability to execute on its strategic goals and market adoption of its products. Please see a detailed description of these and other risks contained in our Annual Report on Form 10-K for the fiscal year ended December 30, 2017, and Quarterly Reports on Form 10-Q for subsequent fiscal quarters, each of which was filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date and will not be updated. Media Contact: Jamie Hall Pascale Communications, LLC. 724-417-0167 jamie@pascalecommunications.com Investor Relations Contact: Lynn Pieper Lewis or Leigh Salvo (415) 937-5404 investors@Iridex.com host Mon, 25 Jun 2018 23:20:00 GMT f1397696-738c-4295-afcd-943feb885714:28 https://iridex.com:443/Default.aspx?tabid=59&articleType=ArticleView&articleId=27#Comments 0 https://iridex.com/DesktopModules/DnnForge%20-%20NewsArticles/RssComments.aspx?TabID=59&ModuleID=524&ArticleID=27 https://iridex.com:443/DesktopModules/DnnForge%20-%20NewsArticles/Tracking/Trackback.aspx?ArticleID=27&PortalID=0&TabID=59 https://iridex.com:443/Default.aspx?tabid=59&articleType=ArticleView&articleId=27 MOUNTAIN VIEW, Calif., June 25, 2018 -- Iridex Corporation (Nasdaq:IRIX), a leading provider of innovative laser systems in ophthalmology, today announced new data was released at the World Ophthalmology Congress in Barcelona, Spain showing that MicroPulse® Laser Therapy with the MicroPulse P3™ Glaucoma Device is safe and effective. New real-world data shows a reduction in IOP close to 50%, with new morphological information elucidating the mechanism of action of the procedure. Ihab Ibrahim Massad, FICO, MD, presented “No More Blades, Scars or Scares: A One Year Experience of MicroPulse Trans-scleral Cyclophotocoagulation from Middle East,” a retrospective chart review of 67 eyes that were treated with MP-TSCPC at a hospital in Jordan. The analysis found that IOP decreased close to 50%, from a mean preoperative IOP of 34.70 mmHg to a mean postoperative IOP of 18.32 mmHg at 1 month and 16.90 mmHg at 12 months. In addition, ocular hypertensive medication use was lowered from 3.45 medications to 2.64 medications at 1 month and 12 months. Only one-third of the eyes in the study had primary open-angle glaucoma, showing the flexibility of the procedure. Shotar Asano, MD, and colleagues in Japan presented, “IOP Reduction and Morphological Changes of the Ciliary Body by MicroPulse Transscleral Cyclophotocoagulation.” The authors investigated postoperative morphological changes of the ciliary body using anterior segment optical coherence tomography (AS-OCT) in eight eyes with refractory glaucoma. AS-OCT analysis revealed that ciliochoroidal effusion (CE) was observed in four out of eight eyes in the inferior sclera at one day after the procedure, and all CE disappeared by two weeks after the procedure. Tim Buckley, Vice President of Global Marketing and Business Development at Iridex explained, “It has long been understood that laser treatment of the ciliary processes will decrease production of aqueous humor. This study shows that there may be an additional mechanism of action in play as well. This speaks to why MP-CPC works so well in a large variety of patients with different types of glaucoma.” Glaucoma is the second most common cause of blindness in the world, and surgical interventions are not always possible for certain patients. MicroPulse Cyclophotocoagulation (CPC) is a safe and effective treatment option for a variety of types of glaucoma, and it can be performed either in the operating room or as an outpatient, office-based procedure. Learn more at treatmyglaucoma.com. The World Ophthalmology Congress is the meeting of the International Council of Ophthalmology and welcomes over 12,000 delegates from more than 100 countries. The meeting includes a scientific program of over 350 sessions addressing all subspecialties and related interests in ophthalmology with 45 Sub-specialty, 39 National, five Regional and four Supranational Societies participating in the program. About Iridex Iridex is a worldwide leader in developing innovative and versatile laser-based medical systems, delivery devices and consumable instrumentation for the ophthalmology market. The Company’s proprietary MicroPulse® technology delivers a differentiated treatment that provides safe, effective, and proven treatment for targeted sight-threatening eye conditions. Iridex’s current product line is used for the treatment of glaucoma, diabetic macular edema (DME) and other retinal diseases. Iridex products are sold in the United States and Germany through a direct sales force and in more than 100 countries through a network of independent distributors. For more information, visit www.Iridex.com. Media Contact: Jamie Hall Pascale Communications, LLC. 724-417-0167 jamie@pascalecommunications.com Investor Relations Contact: Lynn Pieper Lewis or Leigh Salvo (415) 937-5404 investors@Iridex.com host Mon, 25 Jun 2018 23:16:00 GMT f1397696-738c-4295-afcd-943feb885714:27 https://iridex.com:443/Default.aspx?tabid=59&articleType=ArticleView&articleId=26#Comments 0 https://iridex.com/DesktopModules/DnnForge%20-%20NewsArticles/RssComments.aspx?TabID=59&ModuleID=524&ArticleID=26 https://iridex.com:443/DesktopModules/DnnForge%20-%20NewsArticles/Tracking/Trackback.aspx?ArticleID=26&PortalID=0&TabID=59 https://iridex.com:443/Default.aspx?tabid=59&articleType=ArticleView&articleId=26 Mountain View Calif., May 16, 2018 -- Iridex Corporation(Nasdaq: IRIX) today announced that its products will be featured in five poster sessions covering data in a total of 68 eyes focused on open angle, mild to moderate and uncontrolled glaucoma at the 13th European Glaucoma Society Meeting (EGS) in Florence, Italy on May 19-22nd. The EGS is comprised of glaucoma care providers including glaucoma specialists, general ophthalmologists, optometrists, researchers, nurses, technicians, leaders of glaucoma and patient organizations. The posters listed below will showcase Iridex MicroPulse technology. All posters will be available in the poster area. Key Posters: Monday, May 21, 2018 Cigdem Altan, MD: (P4.045) Early Clinical Outcomes of MicroPulse Transcleral Cyclophotocoauglation in Open Angle Glaucoma Walid Zbiba, MD: (P4.081) MicroPulse Transscleral Cyclophotocoagulation in Glaucoma Management: The Tunisian Experience Maria Cecilia Aquino, MD: (P4.097) External MicroPulse Diode Laser Trabeculoplasty for Primary Open Angles Glaucoma: A Pilot Study Tuesday, May 22, 2018 Catherina Josephine Goenad, MD: (P5.016) Early Outcomes of MicroPulse Diode Transscleral Cyclophototherapy for Treatment of Mild to Moderate Glaucoma Beatriz Rodriguez Aguado, MD: (P5.041) Transscleral Cyclophotocoagulation With Diode Laser for Refractory Glaucoma: Our Experience Iridex will also be sponsoring a breakfast symposium titled, “MicroPulse therapy: a choice before, in combination with, and after any other glaucoma treatment.” The symposium will be held on Sunday, May 20th, during the 13th European Glaucoma Society Congress taking place May 19 – 22 in Florence, Italy. A distinguished panel of four ophthalmologists will present the science behind MicroPulse technology, their clinical experience with a variety of patient profiles, and the most recent data on outcomes. “There is a significant increase in the amount of data regarding cyclophotocoagulation with MicroPulse technology. I am excited to share with my colleagues the versatility and success I have seen with the Cyclo G6 Glaucoma Laser System,” said Marc Toeteberg-Harms, MD, FEBO of Switzerland, who will be joined by Ziad Khoueir, MD, MSEd of Lebanon, Ronald de Crom, MD of The Netherlands, and Karin Roswitha Pillunat, MD of Germany for the one-hour reunion that will allow for questions and answers from the attendees. About Iridex Iridex is a worldwide leader in developing innovative and versatile laser-based medical systems, delivery devices and consumable instrumentation for the ophthalmology market. The Company’s proprietary MicroPulse® technology delivers a differentiated treatment that provides safe, effective, and proven treatment for targeted sight-threatening eye conditions. Iridex’s current product line is used for the treatment of glaucoma, diabetic macular edema (DME) and other retinal diseases. Iridex products are sold in the United States and Germany through a direct sales force and in more than 100 countries through a network of independent distributors. For more information, visit Iridex.com/egs. Media Contact: Jamie Hall Pascale Communications, LLC. 724.417.0167 jamie@pascalecommunications.com Investor Relations Contact Lynn Pieper Lewis or Leigh Salvo 415.937.5404 investors@Iridex.com host Fri, 18 May 2018 04:00:00 GMT f1397696-738c-4295-afcd-943feb885714:26 https://iridex.com:443/Default.aspx?tabid=59&articleType=ArticleView&articleId=25#Comments 0 https://iridex.com/DesktopModules/DnnForge%20-%20NewsArticles/RssComments.aspx?TabID=59&ModuleID=524&ArticleID=25 https://iridex.com:443/DesktopModules/DnnForge%20-%20NewsArticles/Tracking/Trackback.aspx?ArticleID=25&PortalID=0&TabID=59 https://iridex.com:443/Default.aspx?tabid=59&articleType=ArticleView&articleId=25 Clinical data on 586 glaucoma patients provides valuable insights for all ophthalmologists. Mountain View Calif., May 02, 2018 -- Iridex Corporation(Nasdaq: IRIX) is pleased to announce that ARVO attendees will have access to over 20 posters presenting data on the use of MicroPulse® technology. Eleven studies cover the use of MicroPulse technology for the treatment of glaucoma while the remaining studies present data on the use of MicroPulse for diverse pathologies including diabetic macular edema, central serous chorioretinopathy, and primary foveal telangiestasis among others. Tim Buckley, Vice President of Marketing, commented on the significant presence of clinical data stating, “There are an exceptional number of physicians that are having success with MicroPulse laser therapy across a variety of applications. It is exciting to see them sharing their data with their peers on how they are improving outcomes for their patients.” Eleven posters share data on a combined 586 glaucoma patients, evaluating various treatment protocols across all stages of glaucoma. Nathan Radcliffe, MD, stated, “Many of my peers and I are all sharing different data on our uses of MicroPulse to treat glaucoma here at ARVO. It is incredibly exciting to see so much clinical evidence supporting the positive outcomes I have seen with my own patients, especially in a therapy with such a high safety profile.” All posters will be available in the exhibit hall throughout the conference, as well as online via www.arvo.org. About Iridex Iridex is a worldwide leader in developing innovative and versatile laser-based medical systems, delivery devices and consumable instrumentation for the ophthalmology market. The Company’s proprietary MicroPulse® technology delivers a differentiated treatment that provides safe, effective, and proven treatment for targeted sight-threatening eye conditions. Iridex’s current product line is used for the treatment of glaucoma, diabetic macular edema (DME) and other retinal diseases.  Iridex products are sold in the United States and Germany through a direct sales force and in more than 100 countries through a network of independent distributors. For more information, visit Iridex.com. Safe Harbor Statement This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Act of 1934, as amended, including those statements concerning the Company’s recall of its TruFocus LIO Premiere product, the company’s anticipated revenue for the fourth quarter and fiscal year 2017 and the timing of the Company’s release of its complete fourth quarter and full fiscal year 2017 results.  These statements are not guarantees of future performance and actual results may differ materially from those described in these forward-looking statements as a result of a number of factors, including adjustments in connection with the Company’s audit of fiscal year 2017.  Please see a detailed description of these and other risks contained in our Annual Report on Form 10-K for the fiscal year ended December 31, 2016, and Quarterly Reports on Form 10-Q for subsequent fiscal quarters, each of which was filed with the Securities and Exchange Commission.  Forward-looking statements contained in this announcement are made as of this date and will not be updated. Media Contact: Jamie Hall Pascale Communications, LLC. 724.417.0167 jamie@pascalecommunications.com Investor Relations Contact Lynn Pieper Lewis or Leigh Salvo 415.937.5404 investors@Iridex.com host Wed, 02 May 2018 18:34:00 GMT f1397696-738c-4295-afcd-943feb885714:25 https://iridex.com:443/Default.aspx?tabid=59&articleType=ArticleView&articleId=22#Comments 0 https://iridex.com/DesktopModules/DnnForge%20-%20NewsArticles/RssComments.aspx?TabID=59&ModuleID=524&ArticleID=22 https://iridex.com:443/DesktopModules/DnnForge%20-%20NewsArticles/Tracking/Trackback.aspx?ArticleID=22&PortalID=0&TabID=59 https://iridex.com:443/Default.aspx?tabid=59&articleType=ArticleView&articleId=22 New iClip™ Closure Device Focused on Glaucoma with Broadening Applications in Other Specialties of Ophthalmology Mountain View, Calif., March 30, 2015 —Iridex Corporation (Nasdaq:IRIX) today announced that the United States Patent and Trademark Office granted the Company a patent for a new proprietary disposable device intended to replace certain suturing techniques in eye surgery. The iClip Closure Device will initially be focused on trabeculectomies and is intended to expand to a broader range of ophthalmic surgical procedures in the future. A trabeculectomy is a common surgical procedure used in the treatment of glaucoma to drain fluid and relieve intraocular pressure. During the procedure, a surgeon removes a piece of tissue in the drainage angle of the eye allowing fluid to bypass the clogged drainage channels. It is estimated that approximately 400,000 trabeculectomies are performed each year worldwide. “Eye surgery is a very delicate and precise process,” stated co-inventor Steven Vold, MD, cataract and glaucoma specialist. “The new iClip technology is intended to drive efficiencies in multiple procedures with an initial focus in glaucoma.” “The iClip is a product that has a broad array of potential applications for eye surgery and is consistent with an integral part of our strategic plan: developing products that provide us new, recurring and therefore, predictable revenue streams,” stated Will Moore, Iridex President and CEO. “Furthermore, we believe ongoing investment in defensible intellectual property creates the opportunity for adding significant shareholder value.” About Iridex Iridex Corporation was founded in 1989 and is a worldwide leader in developing, manufacturing, and marketing innovative and versatile laser-based medical systems, delivery devices and consumable instrumentation for the ophthalmology market. We maintain a deep commitment to the success of our customers, with comprehensive technical, clinical, and service support programs. Iridex is dedicated to a standard of excellence, offering superior technology for superior results. Iridex products are sold in the United States through a direct sales force and internationally through a combination of a direct sales force and a network of approximately 70 independent distributors into over 100 countries. For further information, visit the Iridex website at http://www.Iridex.com/. Safe Harbor Statement This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Act of 1934, as amended, including those statements concerning potential applications for the iClip and other Company products, changes in shareholder value, the protectability and results of any future challenges to the Company’s intellectual property rights, the markets in which the Company operates, trends in treatment and product usage, product plans and future product releases, regulatory approvals, usage and efficacy of Company products, future financial results and the Company’s strategic plans and objectives. These statements are not guarantees of future performance and actual results may differ materially from those described in these forward-looking statements as a result of a number of factors. Please see a detailed description of these and other risks contained in our Annual Report on Form 10-K for the fiscal year ended December 28, 2013, which was filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date and will not be updated. Iridex Contact: Jim Mackanes CFO & COO 650-940-4700 Investor Contact: Matt Clawson Pure Communications, Inc. 949-370-8500 matt@purecommunicationsinc.com host Tue, 31 Mar 2015 17:18:00 GMT f1397696-738c-4295-afcd-943feb885714:22 https://iridex.com:443/Default.aspx?tabid=59&articleType=ArticleView&articleId=21#Comments 0 https://iridex.com/DesktopModules/DnnForge%20-%20NewsArticles/RssComments.aspx?TabID=59&ModuleID=524&ArticleID=21 https://iridex.com:443/DesktopModules/DnnForge%20-%20NewsArticles/Tracking/Trackback.aspx?ArticleID=21&PortalID=0&TabID=59 https://iridex.com:443/Default.aspx?tabid=59&articleType=ArticleView&articleId=21 Initial Orders Include the Recently Patented MicroPulse® P3 Disposable Probe Mountain View, Calif., March 17, 2015 —Iridex Corporation (Nasdaq:IRIX) announced the first commercial sales of its new Cyclo G6 laser system, designed to treat patients diagnosed with a range of glaucoma disease states. The Cyclo G6 system includes a glaucoma dedicated laser along with a family of single use probes, including the newly patented MicroPulse P3 disposable. Glaucoma is an eye disease that causes damage to the optic nerve, which carries images from the retina to the brain. In glaucoma, heightened eye pressure can lead to progressive damage of the delicate nerve fibers of the optic nerve. The Cyclo G6 offers repeatable and minimally invasive approaches to slowing the progress of the disease. “Glaucoma is a chronic disease that requires careful management to preserve a patient’s vision long term,” stated glaucoma and cataract specialist Robert Noecker, MD of the Ophthalmic Consultants of Connecticut. “The procedure performed with the new MicroPulse P3 disposable demonstrated safety and clinical efficacy without the need for incisional surgery.” The market debut of this system was announced at the recent American Glaucoma Society (AGS) congress. Iridex had a particularly strong presence at the AGS meeting that included multiple scientific poster presentations regarding the safety and efficacy of the MicroPulse P3 disposable. The Company hosted daily surgical training labs, which concluded with multiple orders taken. “At the AGS there was a poster from Mexico that presented that costs of glaucoma treatments may represent upwards of 40 percent of a patient’s household income,” stated Will Moore, Iridex President and CEO. “Cost and logistics prohibit the required care for many of these patients, leading to very low rates of compliance and the continual progression towards blindness. To address this situation, we continue to pursue clinically durable and cost effective solutions such as MicroPulse treatment, to address this large and growing patient population.” Glaucoma is the leading cause of adult irreversible blindness. It is estimated that more than 4 million people in the US and approximately 60 million worldwide are afflicted with glaucoma today. About Iridex Iridex Corporation was founded in 1989 and is a worldwide leader in developing, manufacturing, and marketing innovative and versatile laser-based medical systems, delivery devices and consumable instrumentation for the ophthalmology market. We maintain a deep commitment to the success of our customers, with comprehensive technical, clinical, and service support programs. Iridex is dedicated to a standard of excellence, offering superior technology for superior results. Iridex products are sold in the United States through a direct sales force and internationally through a combination of a direct sales force and a network of approximately 70 independent distributors into over 100 countries. For further information, visit the Iridex website at http://www.Iridex.com/. Safe Harbor Statement This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Act of 1934, as amended, including those statements concerning the markets in which the Company operates, trends in treatment and product usage, product plans and future product releases, regulatory approvals, usage and efficacy of Company products, future financial results and the Company’s strategic plans and objectives. These statements are not guarantees of future performance and actual results may differ materially from those described in these forward-looking statements as a result of a number of factors. Please see a detailed description of these and other risks contained in our Annual Report on Form 10-K for the fiscal year ended December 28, 2013, which was filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date and will not be updated. host Wed, 18 Mar 2015 22:34:00 GMT f1397696-738c-4295-afcd-943feb885714:21 https://iridex.com:443/Default.aspx?tabid=59&articleType=ArticleView&articleId=20#Comments 0 https://iridex.com/DesktopModules/DnnForge%20-%20NewsArticles/RssComments.aspx?TabID=59&ModuleID=524&ArticleID=20 https://iridex.com:443/DesktopModules/DnnForge%20-%20NewsArticles/Tracking/Trackback.aspx?ArticleID=20&PortalID=0&TabID=59 https://iridex.com:443/Default.aspx?tabid=59&articleType=ArticleView&articleId=20 Laser Platform Supports Family of Consumable Probes and Appliances Including Recently Patented MicroPulse® P3 Disposable Mountain View, Calif., February 23, 2015 — Iridex Corporation (Nasdaq:IRIX) today announced that it will debut Cyclo G6, the Company’s first laser platform dedicated to the treatment of glaucoma, at this year’s annual congress of the American Glaucoma Society (AGS).  The AGS annual congress is being held February 26 – March 1, 2015, at San Diego’s Hotel del Coronado. Potentially 1,000 members from more than 17 countries are expected to attend the event.  The Cyclo G6 system, which was recently cleared by the US Food and Drug Administration (FDA), is designed to treat patients diagnosed with a range of glaucoma disease states and features the Company’s proprietary MicroPulse tissue-sparing technology and a family of single use probes that connect to an intuitive, user-friendly laser console.  MicroPulse offers a repeatable, minimally invasive approach to slowing the progress of the disease and pushing off the need for more invasive surgical intervention. In addition to the product unveiling, Iridex announced that a scientific poster presentation entitled, “MicroPulse Trans-scleral Cyclophotocoagulation (mTSCPC) for the Treatment of Glaucoma using the MicroPulse P3 Device,” will feature results from early clinical application of the new MicroPulse P3 disposable.  The poster will be presented on Friday, February 27, from 7-8 am PT and is authored by leading glaucoma specialists Drs. Nathan Radcliffe, Ike Ahmed, Jeffrey Kammer, Anup Khatana, Robert Noecker and Steven Vold. "Glaucoma is a chronic disease with an increasing incidence rate that is in need of innovative interventions to preserve vision," said inventor of the MicroPulse P3 device, Professor Paul Chew, MBBS, MMed(Ophth), FRCSEd, FRCOphth, FAMS of the National University of Singapore.  “A MicroPulse based consumable appliance with a characteristic high safety profile that leaves future treatment options open, is clinically repeatable, and that does not require incisional surgery, is a very compelling alternative." “Our proprietary Cyclo G6 platform allows Iridex to participate in both hardware and the faster growing procedural side of the glaucoma market, representing a new and more predictable recurring revenue stream,” stated Will Moore, Iridex President and CEO.  “The cost and logistics of administering glaucoma medications is a burden to both the patient and healthcare organizations; furthermore, patients using prescribed medications have a poor record of compliance.  Thus, a durable, cost-effective solution continues to be our focus as the world continues the trend toward value-based medicine.” Glaucoma is the leading cause of adult irreversible blindness.  It is estimated that more than 4 million people in the US and approximately 60 million worldwide are afflicted with glaucoma today. About Iridex Iridex Corporation was founded in 1989 and is a worldwide leader in developing, manufacturing, and marketing innovative and versatile laser-based medical systems, delivery devices and consumable instrumentation for the ophthalmology market. We maintain a deep commitment to the success of our customers, with comprehensive technical, clinical, and service support programs. Iridex is dedicated to a standard of excellence, offering superior technology for superior results. Iridex products are sold in the United States through a direct sales force and internationally through a combination of a direct sales force and a network of approximately 70 independent distributors into over 100 countries. For further information, visit the Iridex website at http://www.Iridex.com/.   Safe Harbor Statement This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Act of 1934, as amended, including those statements concerning the markets in which the Company operates, trends in treatment and product usage, product plans and future product releases, regulatory approvals, usage and efficacy of Company products, future financial results and the Company’s strategic plans and objectives. These statements are not guarantees of future performance and actual results may differ materially from those described in these forward-looking statements as a result of a number of factors. Please see a detailed description of these and other risks contained in our Annual Report on Form 10-K for the fiscal year ended December 28, 2013, which was filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date and will not be updated.   Iridex Contact:                                           Investor Contact:   Jim Mackaness                                               Matt Clawson CFO & COO                                                  Pure Communications, Inc. 650-940-4700                                                 949-370-8500                                                                         matt@purecommunicationsinc.com   host Sat, 28 Feb 2015 03:06:00 GMT f1397696-738c-4295-afcd-943feb885714:20 https://iridex.com:443/Default.aspx?tabid=59&articleType=ArticleView&articleId=18#Comments 0 https://iridex.com/DesktopModules/DnnForge%20-%20NewsArticles/RssComments.aspx?TabID=59&ModuleID=524&ArticleID=18 https://iridex.com:443/DesktopModules/DnnForge%20-%20NewsArticles/Tracking/Trackback.aspx?ArticleID=18&PortalID=0&TabID=59 https://iridex.com:443/Default.aspx?tabid=59&articleType=ArticleView&articleId=18 Read full article host Fri, 30 May 2014 21:30:00 GMT f1397696-738c-4295-afcd-943feb885714:18 https://iridex.com:443/Default.aspx?tabid=59&articleType=ArticleView&articleId=17#Comments 0 https://iridex.com/DesktopModules/DnnForge%20-%20NewsArticles/RssComments.aspx?TabID=59&ModuleID=524&ArticleID=17 https://iridex.com:443/DesktopModules/DnnForge%20-%20NewsArticles/Tracking/Trackback.aspx?ArticleID=17&PortalID=0&TabID=59 https://iridex.com:443/Default.aspx?tabid=59&articleType=ArticleView&articleId=17 Read the full article host Fri, 18 Apr 2014 23:22:00 GMT f1397696-738c-4295-afcd-943feb885714:17 https://iridex.com:443/Default.aspx?tabid=59&articleType=ArticleView&articleId=16#Comments 0 https://iridex.com/DesktopModules/DnnForge%20-%20NewsArticles/RssComments.aspx?TabID=59&ModuleID=524&ArticleID=16 https://iridex.com:443/DesktopModules/DnnForge%20-%20NewsArticles/Tracking/Trackback.aspx?ArticleID=16&PortalID=0&TabID=59 https://iridex.com:443/Default.aspx?tabid=59&articleType=ArticleView&articleId=16 Click to read the full article host Fri, 28 Feb 2014 23:33:00 GMT f1397696-738c-4295-afcd-943feb885714:16 https://iridex.com:443/Default.aspx?tabid=59&articleType=ArticleView&articleId=15#Comments 0 https://iridex.com/DesktopModules/DnnForge%20-%20NewsArticles/RssComments.aspx?TabID=59&ModuleID=524&ArticleID=15 https://iridex.com:443/DesktopModules/DnnForge%20-%20NewsArticles/Tracking/Trackback.aspx?ArticleID=15&PortalID=0&TabID=59 https://iridex.com:443/Default.aspx?tabid=59&articleType=ArticleView&articleId=15 Click to read the full article host Wed, 12 Feb 2014 17:37:00 GMT f1397696-738c-4295-afcd-943feb885714:15 https://iridex.com:443/Default.aspx?tabid=59&articleType=ArticleView&articleId=13#Comments 0 https://iridex.com/DesktopModules/DnnForge%20-%20NewsArticles/RssComments.aspx?TabID=59&ModuleID=524&ArticleID=13 https://iridex.com:443/DesktopModules/DnnForge%20-%20NewsArticles/Tracking/Trackback.aspx?ArticleID=13&PortalID=0&TabID=59 https://iridex.com:443/Default.aspx?tabid=59&articleType=ArticleView&articleId=13 Click to see full interview. host Wed, 30 Oct 2013 15:20:00 GMT f1397696-738c-4295-afcd-943feb885714:13 https://iridex.com:443/Default.aspx?tabid=59&articleType=ArticleView&articleId=12#Comments 0 https://iridex.com/DesktopModules/DnnForge%20-%20NewsArticles/RssComments.aspx?TabID=59&ModuleID=524&ArticleID=12 https://iridex.com:443/DesktopModules/DnnForge%20-%20NewsArticles/Tracking/Trackback.aspx?ArticleID=12&PortalID=0&TabID=59 https://iridex.com:443/Default.aspx?tabid=59&articleType=ArticleView&articleId=12 Read more host Tue, 10 Sep 2013 16:11:00 GMT f1397696-738c-4295-afcd-943feb885714:12 https://iridex.com:443/Default.aspx?tabid=59&articleType=ArticleView&articleId=11#Comments 0 https://iridex.com/DesktopModules/DnnForge%20-%20NewsArticles/RssComments.aspx?TabID=59&ModuleID=524&ArticleID=11 https://iridex.com:443/DesktopModules/DnnForge%20-%20NewsArticles/Tracking/Trackback.aspx?ArticleID=11&PortalID=0&TabID=59 https://iridex.com:443/Default.aspx?tabid=59&articleType=ArticleView&articleId=11 To learn why, Register Today! host Thu, 16 May 2013 22:21:00 GMT f1397696-738c-4295-afcd-943feb885714:11 https://iridex.com:443/Default.aspx?tabid=59&articleType=ArticleView&articleId=8#Comments 0 https://iridex.com/DesktopModules/DnnForge%20-%20NewsArticles/RssComments.aspx?TabID=59&ModuleID=524&ArticleID=8 https://iridex.com:443/DesktopModules/DnnForge%20-%20NewsArticles/Tracking/Trackback.aspx?ArticleID=8&PortalID=0&TabID=59 https://iridex.com:443/Default.aspx?tabid=59&articleType=ArticleView&articleId=8 Click here to watch testimonial by Steven D. Vold, M.D. host Thu, 15 Nov 2012 23:15:00 GMT f1397696-738c-4295-afcd-943feb885714:8 https://iridex.com:443/Default.aspx?tabid=59&articleType=ArticleView&articleId=7#Comments 0 https://iridex.com/DesktopModules/DnnForge%20-%20NewsArticles/RssComments.aspx?TabID=59&ModuleID=524&ArticleID=7 https://iridex.com:443/DesktopModules/DnnForge%20-%20NewsArticles/Tracking/Trackback.aspx?ArticleID=7&PortalID=0&TabID=59 https://iridex.com:443/Default.aspx?tabid=59&articleType=ArticleView&articleId=7 Iridex’ patented MicroPulseTM laser technology enables Fovea-friendlyTM therapy for sight-threatening eye diseases Mountain View Calif., November 9, 2012— Iridex Corporation (Nasdaq: IRIX) today announced that Iridex and QUANTEL Medical have signed a global patent licensing agreement that gives QUANTEL access to Iridex’ MicroPulse technology. Our proprietary technology provides ophthalmologists a noninvasive treatment for sight-threatening diseases of the eye, including complications associated with diabetes. Unlike conventional laser therapy, MicroPulse spares the eye tissue responsible for vision while producing comparable clinical effect to traditional methods that destroy tissue. “There is a significant need in the market place for efficient and durable therapies for retinal diseases associated with the growth of diabetes and the aging population,” stated Will Moore, Iridex President and CEO. He continued, “With 10-year follow up data, a growing global user base, and significant patent protection, MicroPulse is emerging as a future standard of care.” The license agreement will allow QUANTEL to market and display Iridex’ MicroPulse technology for their range of high quality clinical lasers and is the next step in gaining broad market availability of MicroPulse photocoagulation lasers. Both QUANTEL and Iridex offer a full line of laser systems that offer standard photocoagulation in addition to MicroPulse Laser Therapy. Moore continued, “Further establishing the MicroPulse brand and technology as an Iridex property is critical as the market continues to recognize its broad applicability for retina and other procedures. We look forward to working with others in the industry as it migrates toward a new standard for laser therapy in additional segments.” “The global clinical evidence supporting Iridex’ MicroPulse laser technology was an important factor in this decision,” stated Mr. Jean-Marc Gendre, CEO of QUANTEL Medical. He continued, “By aligning our market strategies with another industry leader, we believe the ophthalmic community will have greater access to MicroPulse technology, helping to improve the standard of care for retinal diseases. We also believe that this collaboration will be the most efficient method to standardize MicroPulse clinical protocols for our customers.” About MicroPulse Technology MicroPulse is a Fovea-friendly, tissue-sparing laser delivery therapy that works by electronically “chopping” the laser emission into trains of microsecond pulses. This enhances the physician’s ability to more precisely control the laser effects on target tissues, offering the potential for ocular treatment with less collateral effects than conventional laser treatments. About Iridex Iridex Corporation was founded in 1989 and is a worldwide leader in developing, manufacturing, and marketing innovative and versatile laser-based medical systems, delivery devices and consumable instrumentation for the ophthalmology market. We maintain a deep commitment to the success of our customers, with comprehensive technical, clinical, and service support programs. Iridex is dedicated to a standard of excellence, offering superior technology for superior results. Iridex products are sold in the United States through a direct sales force and internationally through a combination of a direct sales force and a network of approximately 70 independent distributors into over 100 countries. For further information, visit the Iridex website at http://www.Iridex.com/. About QUANTEL Medical Founded in 1993 and headquartered in Clermont-Ferrand, France, QUANTEL Medical is a global ophthalmic medical device company dedicated to developing leading technologies to improve the treatment of ocular diseases. QUANTEL Medical has a strong emphasis in research and development, resulting in many first-to-market product introductions, and a comprehensive product portfolio of diagnostic ultrasound and surgical lasers for ophthalmologists. The products are available through direct sales operations in the U.S. and France, and through independent distributors in over 90 countries. QUANTEL Medical is a division of Quantel (QUA:EN), a world-wide leader in the development of solid-state lasers for scientific and industrial applications. www.quantel-medical.com. Safe Harbor Statement This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Act of 1934, as amended, relating to Iridex’s strategy and its ability to execute on that strategy, the ability to increase shareholder value, the size and growth of markets in which Iridex operates, the success of Iridex’s marketing and sales efforts, and the effectiveness and market acceptance of MicroPulse laser therapy. These statements are not guarantees of future performance and actual results may differ materially from those described in these forward-looking statements as a result of a number of factors. Please see a detailed description of these and other risks contained in our Annual Report on Form 10-K for the fiscal year ended December 31, 2011, and our Quarterly Reports on Form 10-Q for the fiscal quarters ended March 31, 2012, June 30, 2012, and September 29, 2012, each of which was filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date and will not be updated. host Thu, 15 Nov 2012 23:13:00 GMT f1397696-738c-4295-afcd-943feb885714:7